<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Blood Adv</journal-id><journal-id journal-id-type="iso-abbrev">Blood Adv</journal-id><journal-title-group><journal-title>Blood Advances</journal-title></journal-title-group><issn pub-type="ppub">2473-9529</issn><issn pub-type="epub">2473-9537</issn><publisher><publisher-name>The American Society of Hematology</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39374575</article-id><article-id pub-id-type="pmc">PMC7617191</article-id><article-id pub-id-type="pii">S2473-9529(24)00602-5</article-id><article-id pub-id-type="doi">10.1182/bloodadvances.2024014046</article-id><article-categories><subj-group subj-group-type="heading"><subject>Hematopoiesis and Stem Cells</subject></subj-group></article-categories><title-group><article-title>Maintenance of hematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition<sup><xref ref-type="fn" rid="d36e682">&#x02217;</xref></sup><sup><xref ref-type="fn" rid="d36e686">&#x02020;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Williams</surname><given-names>Matthew J.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Wang</surname><given-names>Xiaonan</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Bastos</surname><given-names>Hugo P.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Grondys-Kotarba</surname><given-names>Gabriela</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Wu</surname><given-names>Qin</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Jin</surname><given-names>Shucheng</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Johnson</surname><given-names>Carys</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Mende</surname><given-names>Nicole</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Calderbank</surname><given-names>Emily</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Wantoch</surname><given-names>Michelle</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Park</surname><given-names>Hyun Jung</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Mantica</surname><given-names>Giovanna</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au13"><name><surname>Hannah</surname><given-names>Rebecca</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au14"><name><surname>Wilson</surname><given-names>Nicola K.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au15"><name><surname>Pask</surname><given-names>Dean C.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au16"><name><surname>Hamilton</surname><given-names>Tina L.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au17"><name><surname>Kinston</surname><given-names>Sarah J.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au18"><name><surname>Asby</surname><given-names>Ryan</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au19"><name><surname>Sneade</surname><given-names>Rachel</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au20"><name><surname>Baxter</surname><given-names>E. Joanna</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au21"><name><surname>Campbell</surname><given-names>Peter</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au22"><name><surname>Vassiliou</surname><given-names>George S.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au23"><name><surname>Laurenti</surname><given-names>Elisa</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au24"><name><surname>Li</surname><given-names>Juan</given-names></name><email>jl257@cam.ac.uk</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor3" ref-type="corresp">&#x02217;&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au25"><name><surname>G&#x000f6;ttgens</surname><given-names>Berthold</given-names></name><email>bg200@cam.ac.uk</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au26"><name><surname>Green</surname><given-names>Anthony R.</given-names></name><email>arg1000@cam.ac.uk</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>1</label>Department of Haematology, Wellcome&#x02013;Medical Research Council Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom</aff><aff id="aff2"><label>2</label>Department of Haematology, University of Cambridge, Cambridge, United Kingdom</aff><aff id="aff3"><label>3</label>Department of Public Health, School of Public Health, Shanghai Jiaotong University School of Medicine, Shanghai, China</aff><aff id="aff4"><label>4</label>Flow Facility, Cambridge Institute for Medical Research, Cambridge, United Kingdom</aff><aff id="aff5"><label>5</label>Department of Cancer Genomics, Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Correspondence: Anthony R. Green, Wellcome&#x02013;Medical Research Council Cambridge Stem Cell Institute, Department of Haematology, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, CB2 0AW, United Kingdom; <email>arg1000@cam.ac.uk</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Berthold G&#x000f6;ttgens, Wellcome&#x02013;Medical Research Council Cambridge Stem Cell Institute, Department of Haematology, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, CB2 0AW, United Kingdom; <email>bg200@cam.ac.uk</email></corresp><corresp id="cor3"><label>&#x02217;&#x02217;&#x02217;</label>Juan Li, Wellcome&#x02013;Medical Research Council Cambridge Stem Cell Institute, Department of Haematology, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, CB2 0AW, United Kingdom; <email>jl257@cam.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>10</day><month>10</month><year>2024</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>28</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>10</day><month>10</month><year>2024</year></pub-date><volume>9</volume><issue>2</issue><fpage>291</fpage><lpage>309</lpage><history><date date-type="received"><day>20</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>9</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by The American Society of Hematology.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The American Society of Hematology</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0010"><title>Key Points</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Tyrosine-unphosphorylated STAT5 maintains HSCs.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">JAK inhibition promotes unphosphorylated STAT5 activity and maintains normal and myeloproliferative neoplasm HSPCs in mice and humans.</p></list-item></list></p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Visual Abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="BLOODA_ADV-2024-014046-ga1"/></fig></abstract><abstract id="abs0020"><title>Abstract</title><p>Adult hematopoietic stem cells (HSCs) are responsible for the lifelong production of blood and immune cells, a process regulated by extracellular cues, including cytokines. Many cytokines signal through the conserved Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in which tyrosine-phosphorylated STATs (pSTATs) function as transcription factors. STAT5 is a pivotal downstream mediator of several cytokines known to regulate hematopoiesis, but its function in the HSC compartment remains poorly understood. In this study, we show that STAT5-deficient HSCs exhibit an unusual phenotype, including reduced multilineage repopulation and self-renewal, combined with reduced exit from quiescence and increased differentiation. This was driven not only by the loss of canonical pSTAT5 signaling, but also by the loss of distinct transcriptional functions mediated by STAT5 that lack canonical tyrosine phosphorylation (uSTAT5). Consistent with this concept, expression of an unphosphorylatable STAT5 mutant constrained wild-type HSC differentiation, promoted their maintenance, and upregulated transcriptional programs associated with quiescence and stemness. The JAK1/2 inhibitor, ruxolitinib, which increased the uSTAT5:pSTAT5 ratio, had similar effects on murine HSC function; it constrained HSC differentiation and proliferation, promoted HSC maintenance, and upregulated transcriptional programs associated with stemness. Ruxolitinib also enhanced serial replating of normal human hematopoietic stem and progenitor cells (HSPCs), calreticulin-mutant murine HSCs, and HSPCs obtained from patients with myelofibrosis. Our results therefore reveal a previously unrecognized interplay between pSTAT5 and uSTAT5 in the control of HSC function and highlight JAK inhibition as a potential strategy for enhancing HSC function during ex&#x000a0;vivo culture. Increased levels of uSTAT5 may also contribute to the failure of JAK inhibitors to eradicate myeloproliferative neoplasms.</p></abstract></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0020">Hematopoietic stem cells (HSCs) are a highly quiescent population of cells responsible for continued production of mature blood cells throughout life.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Their ability to respond to environmental signals is important for the maintenance of homeostasis and for HSCs to respond to a variety of stresses.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref></p><p id="p0025">The Janus kinase (JAK)&#x02013;signal transducer and activator of transcription (STAT) pathway regulates multiple developmental and adult stem cell populations<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> and is dysregulated in a variety of hematologic malignancies and other cancers.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> The STAT5 is an essential downstream mediator of cytokine signaling at multiple stages of hematopoiesis.<xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref> In eutherian mammals, 2 closely related STAT5 isoforms,<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> STAT5A and STAT5B, display distinct and redundant functions in different cell types.<xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref> Mice that lack both genes, or the N-terminal domains of both genes, develop severe anemia and leukopenia<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref> that are associated with reduced survival and proliferation of erythroblasts.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Conversely, high levels of STAT5 activity in hematopoietic stem and progenitor cells (HSPCs) drive erythroid differentiation.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref></p><p id="p0030">STAT5A and STAT5B contain critical regulatory tyrosine residues (Y694 and Y699) that are essential for the activation of canonical tyrosine-phosphorylated STAT5 (pSTAT5) target genes.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> These residues are phosphorylated by (JAKs<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> that are activated in response to multiple cytokines,<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref> including interleukin-3 (IL-3)<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> and thrombopoietin.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> pSTAT5 accumulates in the nucleus, binds to DNA, and regulates the transcription of target genes.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> STAT5 phosphorylation is transient because pSTAT5 rapidly promotes the expression of negative regulators of JAK-STAT signaling, including suppressors of cytokine signaling, tyrosine phosphatases, and protein inhibitors of STATs.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref></p><p id="p0035">Elevated STAT5 phosphorylation is observed in many hematologic malignancies<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> and solid tumors.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Activation of the JAK-STAT pathway is especially common in the myeloproliferative neoplasms (MPNs), &#x0003e;90% of which contain driver mutations that activate JAK-STAT signaling.<xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref> JAK inhibitors are used to treat patients with MPN with advanced disease,<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> but although these can lead to symptomatic improvement, they rarely reduce the allele burden,<xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref> suggesting that they fail to eradicate malignant HSCs.</p><p id="p0040">Loss of both STAT5 genes lead to a reduction in the number of immunophenotypically-defined HSCs<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> and defective repopulation by fetal liver and adult bone marrow (BM).<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> STAT5B is dominant in multipotent HPC7 cells<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> and STAT5B deficient, but not STAT5A deficient, BM showed functional defects in serial transplants.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> However, several aspects of STAT5 function in HSPCs remain unclear or have been the subject of conflicting reports. Both an increase<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> and a reduction in cycling<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref> have been observed in HSPCs after STAT5 loss, whereas STAT5 phosphorylation is associated with increased proliferation.<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> Moreover, both STAT5 knockdown<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> and constitutively active STAT5A overexpression<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> have been reported to increase HSPC differentiation. Insight into at least some of these apparent paradoxes came from the demonstration that STAT5 that lacks phosphorylation of its critical tyrosine (uSTAT5) is present in the nucleus of HSPCs and represses megakaryocytic differentiation by restricting access of the megakaryocytic transcription factors to target genes.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> Cytokine-mediated phosphorylation of STAT5 therefore triggers 2 distinct transcriptional consequences, namely activation of a canonical pSTAT5&#x02013;driven program that regulates proliferation and apoptosis and loss of a uSTAT5 program that restrains megakaryocytic differentiation.</p><p id="p0045">Given our limited understanding of the function of STAT5 in HSCs and the complete lack of information about the role of uSTAT5 in primitive HSCs, we explored these issues using genetically modified mice.</p></sec><sec id="sec2"><title>Methods</title><sec id="sec2.1"><title>Mice</title><p id="p0050">The wild-type (WT) C57BL/6 (CD45.2), C57BL/6.SJL (CD45.1), and F1 (CD45.1/CD45.2) mice, and calreticulin (CALR):del mutant mice<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> in this study were used at 10 to 32&#x000a0;weeks of age. STAT5<sup>fl/fl</sup>mice<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> were kindly gifted by Lothar Hennighausen and were crossed with Mx1Cre mice<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> to generate STAT5<sup>fl/fl</sup> with Cre (STAT5<sup>fl/fl</sup>Cre<sup>+</sup>) or without Cre (STAT5<sup>fl/fl</sup>Cre<sup>&#x02212;</sup>). STAT5 deletion was induced by repeated injections with polyinosinic:polycytidylic acid (Poly:IC). All mice were kept in pathogen-free conditions, and all procedures were performed according to the UK Home Office regulations.</p></sec><sec id="sec2.2"><title>Smart-seq2 and 10x Genomics single-cell RNA sequencing (scRNAseq) analysis</title><p id="p0055">Single Lin<sup>&#x02212;</sup>CD150<sup>+</sup>CD45<sup>+</sup>CD48<sup>&#x02212;</sup>EPCR<sup>+</sup> (ESLAM) HSCs were sorted from bone marrow mononuclear cells (BMMNCs) using fluorescence-activated cell sorting and processed using Smart-seq2 (accession number: <ext-link ext-link-type="NCBI:geo" xlink:href="GSE223366" id="intref0010">GSE223366</ext-link>). Lineage<sup>&#x02212;</sup>cKit<sup>+</sup> (LK) cells were sorted from BMMNCs and processed using 10x Chromium (10x Genomics, Pleasanton, CA; GSE223632). Sorted ESLAM HSCs were transduced with lentivirus containing empty vector (EV), STAT5B-WT, or STAT5B-Y699F (YF). After a 5-day culture, green fluorescent protein&#x02013;positive (GFP<sup>+</sup>) DAPI<sup>&#x02212;</sup> (4&#x02032;,6-diamidino-2-phenylindole&#x02013;negative) cells were processed using 10x Chromium (10x Genomics; GSE223680). Sorted ESLAM HSCs were cultured for 5&#x000a0;days with ruxolitinib or dimethyl sulfoxide (DMSO), which were then processed using 10x Chromium (10x Genomics; GSE260462). All data were deposited in the National Center for Biotechnology Information Gene Expression Omnibus.</p><p id="p0060">An institutional review board/research ethics committee approved the protocol for human samples.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>STAT5 loss leads to defective HSC function</title><p id="p0065">Previous reports showed that STAT5<sup>&#x02212;/&#x02212;</sup> fetal liver and adult BM cells displayed reduced repopulation in transplantation assays,<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> but it was unclear if this was a consequence of reduced HSC number or whether STAT5<sup>&#x02212;/&#x02212;</sup> HSCs are also functionally impaired. We therefore crossed mice that carried a floxed <italic>Stat5a/5b</italic> allele<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> with Mx1Cre mice and used Poly:IC to delete both <italic>Stat5a</italic> and <italic>Stat5b</italic> loci with &#x0223c;90% efficiency in hematopoietic cells (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;1</xref>A-C).</p><p id="p0070">Consistent with previous reports,<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> a STAT5 deletion led to anemia, leukopenia, and reduced BM cellularity (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;1</xref>D-E). In STAT5-deficient BM, the frequencies of immunophenotypic primitive HSCs (both ESLAM; Lin<sup>&#x02212;</sup>CD150<sup>+</sup>CD45<sup>+</sup>CD48<sup>&#x02212;</sup>EPCR<sup>+</sup>, and long-term HSC [LT-HSC]; Lin<sup>&#x02212;</sup>Sca1<sup>+</sup>cKit<sup>+</sup>CD150<sup>+</sup>CD48<sup>&#x02212;</sup>CD34<sup>&#x02212;</sup>Flk2<sup>&#x02212;</sup>; <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A-B) and B cells (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C) were reduced and the proportion of erythroid progenitors (colony forming unit-erythroid [CFU-e]; Lin<sup>&#x02212;</sup>Sca1<sup>&#x02212;</sup>cKit<sup>+</sup>CD41<sup>&#x02212;</sup>CD16/32<sup>&#x02212;</sup>CD105<sup>+</sup>CD150<sup>&#x02212;</sup>) was increased (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D), but other mature and progenitor cell types were unaltered (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;1</xref>F-I). In the spleen, STAT5 deletion reduced the B-cell frequency (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;1</xref>J) and increased the frequencies of erythroid progenitors (CFU-e and PreCFU-e; Lin<sup>&#x02212;</sup>Sca1<sup>&#x02212;</sup>cKit<sup>+</sup>CD41<sup>&#x02212;</sup>CD16/32<sup>&#x02212;</sup>CD105<sup>+</sup>CD150<sup>+</sup>) and all stages of erythroblast differentiation (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>E-F).<fig id="fig1"><label>Figure&#x000a0;1.</label><caption><p><bold>STAT5 loss leads to defective HSC function.</bold> (A) Bar plot showing the frequency of ESLAM HSCs (CD45<sup>+</sup>CD150<sup>+</sup>CD48<sup>&#x02212;</sup>EPCR<sup>+</sup>) in BMMNCs from WT and STAT5-deficient mice (mean&#x000a0;&#x000b1; standard error of the mean [SEM]). (B) Bar plot showing the frequency of LT-HSCs (Lin<sup>&#x02212;</sup>Sca1<sup>&#x02212;</sup>cKit<sup>+</sup>CD150<sup>+</sup>CD48<sup>&#x02212;</sup>CD34<sup>&#x02212;</sup>Flk2<sup>&#x02212;</sup>) in BMMNCs (mean&#x000a0;&#x000b1; SEM). (C) Bar plot showing the frequency of B cells (B220<sup>+</sup>) in BMMNCs (mean&#x000a0;&#x000b1; SEM). (D) Bar plot showing the frequency of CFU-e progenitors (Lin<sup>&#x02212;</sup>Sca1<sup>&#x02212;</sup>cKit<sup>+</sup>CD41<sup>&#x02212;</sup>CD16/32<sup>&#x02212;</sup>CD105<sup>+</sup>CD150<sup>&#x02212;</sup>) in BMMNCs (mean&#x000a0;&#x000b1; SEM). (E) Bar plots showing the frequency of CFU-e and pre&#x02013;CFU-e (Lin<sup>&#x02212;</sup>Sca1<sup>&#x02212;</sup>cKit<sup>+</sup>CD41<sup>&#x02212;</sup>CD16/32<sup>&#x02212;</sup>CD105<sup>+</sup>CD150<sup>+</sup>) cells in spleen mononuclear cells (mean&#x000a0;&#x000b1; SEM). (F) Bar plots (left) showing the frequency of megakaryocyte (CD41<sup>+</sup>CD42<sup>+</sup>) and erythroid precursor cells (I, CD71<sup>hi</sup>Ter119<sup>mid</sup>; II, CD71<sup>hi</sup>Ter119<sup>hi</sup>; III, CD71<sup>mid</sup>Ter119<sup>hi</sup>; IV, CD71<sup>low</sup>Ter119<sup>hi</sup>) in spleen mononuclear cells (mean&#x000a0;&#x000b1; SEM) with a representative flow-cytometry plot (right) showing the gating of different stages of erythroid precursor cells in terminal differentiation. (G) Schematic diagram showing that 33 fluorescence-activated cell sorting&#x02013;purified BM ESLAM HSCs were transplanted into irradiated recipient mice with 5&#x000a0;&#x000d7; 10<sup>5</sup> competitor BMMNCs. STAT5 was deleted in Cre<sup>+</sup> donor cells after transplantation by repeated injection (&#x000d7;7) with Poly:IC in recipients. Blood was taken before and after STAT5 deletion and was followed for 5&#x000a0;months after deletion before serial transplantation of 3&#x000a0;&#x000d7; 10<sup>6</sup> primary recipient BMMNCs. (H) Connected line graphs showing donor chimerism in peripheral blood mononuclear cells at each time point in primary and secondary recipients (mean&#x000a0;&#x000b1; SEM). The dotted line indicates initiation of the Poly:IC injections. The asterisks indicate significant differences by analysis of variance column factor (&#x02217;&#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .0001). (I)&#x000a0;Bar plots showing the total BMMNC donor chimerism in primary and secondary recipients (mean&#x000a0;&#x000b1; SEM). (J) Bar plots showing LT-HSC donor chimerism in primary and secondary recipients (mean&#x000a0;&#x000b1; SEM). The asterisks indicate significant differences by Student <italic>t</italic> test (&#x02217;&#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .0001; &#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .001; &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .01; &#x02217;<italic>P</italic>&#x000a0;&#x0003c; .05) unless otherwise indicated.</p></caption><graphic xlink:href="BLOODA_ADV-2024-014046-gr1ah"/><graphic xlink:href="BLOODA_ADV-2024-014046-gr1ij"/></fig></p><p id="p0075">Droplet-based (10x Genomics) scRNAseq was performed to assess the HSPC landscape. BM LK (Lin<sup>&#x02212;</sup>cKit<sup>+</sup>) cells from pairs of STAT5<sup>&#x02212;/&#x02212;</sup> and WT control mice were projected onto a previously published LK data set<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> and then onto a phenotypically-defined HSPC data set;<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> cell types were annotated based on their nearest neighbors. Cells within the LT-HSC, short-term HSC (ST-HSC), multipotent progenitor (MPP), myeloid, and early- and miderythroid clusters were relatively reduced in STAT5<sup>&#x02212;/&#x02212;</sup> mice, whereas the abundance of cells within late-erythroid and lymphoid clusters were relatively increased (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;1</xref>K). These results confirm and extend previous reports and show that a STAT5 deficiency causes widespread alterations in hematopoietic progenitors, including reduced numbers of HSCs.</p><p id="p0080">In competitive transplantation experiments using highly purified ESLAM HSCs (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>G; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;1</xref>L), STAT5-deficient HSCs displayed significantly reduced multilineage repopulation in the blood (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>H; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;1</xref>M-O) and BM (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>I; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;1</xref>P) of primary recipients. There&#x000a0;was almost no repopulation of blood or BM in secondary recipients. Few or no STAT5-deficient LT-HSCs (Lin<sup>&#x02212;</sup>Sca1<sup>+</sup>cKit<sup>+</sup>CD150<sup>+</sup>CD48<sup>&#x02212;</sup>CD34<sup>&#x02212;</sup>Flk2<sup>&#x02212;</sup>CD45.1<sup>&#x02212;</sup>CD45.2<sup>+</sup>) were observed in the BM of primary or secondary recipients (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>J; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;1</xref>Q). These data demonstrate that STAT5-deficient HSCs are not merely reduced in number but are also functionally impaired and display markedly reduced multilineage repopulation and self-renewal.</p></sec><sec id="sec3.2"><title>STAT5-deficient HSCs display reduced cell cycle entry, increased differentiation, and reduced generation of lineage-negative progeny</title><p id="p0085">To explore the molecular basis for HSC dysfunction, plate-based scRNAseq was performed on WT and STAT5-deficient ESLAM HSCs (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;2</xref>A-C) and led to the identification of 308 differentially expressed genes (adjusted <italic>P</italic>&#x000a0;&#x0003c; .01; log fold change greater than&#x000a0;&#x000b1;0.5; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;2</xref>D; <xref rid="appsec1" ref-type="sec">supplemental Table&#x000a0;1</xref>), including canonical STAT5 targets (eg, <italic>Cish</italic>, <italic>Socs2</italic> and <italic>Bcl6</italic>; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;2</xref>E).</p><p id="p0090">Gene set enrichment analysis identified 12 signatures that were enriched in STAT5-deficient ESLAM HSCs (false discovery rate &#x0003c;0.25; <xref rid="appsec1" ref-type="sec">supplemental Table&#x000a0;2</xref>), including the Wnt, Hedgehog and Kras pathways, and 35 signatures that were depleted (false discovery rate &#x0003c;0.25; <xref rid="appsec1" ref-type="sec">supplemental Table&#x000a0;2</xref>), including JAK-STAT signaling, DNA repair, and the unfolded protein response. The most significantly depleted gene sets were cell cycle&#x02013;related signatures, including E2F targets and DNA replication (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;2</xref>F). Consistent with this observation, analysis of our separate 10X LK cell data sets showed that, when compared with WT controls, far fewer STAT5-deficient LT-HSCs were in cycle (8.58% vs 2.82%; <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B). A less pronounced reduction in cell cycling was seen in STAT5-deficient ST-HSCs and MPPs.<fig id="fig2"><label>Figure&#x000a0;2.</label><caption><p><bold>STAT5-deficient HSCs display reduced cell cycle entry, increased differentiation, and reduced retention of lineage-negative progeny.</bold> (A) Gene set enrichment analysis (GSEA) plots showing depleted cell cycle&#x02013;related signatures in STAT5-deficient ESLAM (CD45<sup>+</sup>CD150<sup>+</sup>CD48<sup>&#x02212;</sup>EPCR<sup>+</sup>) HSCs. scRNAseq analysis using the Smart-seq platform was performed on FACS-isolated ESLAM HSCs from STAT5<sup>f/f</sup> Cre- or STAT5<sup>f/f</sup> Cre<sup>+</sup> BM; 132 STAT5-deficient and 132 WT HSCs passed quality control and were used for downstream analysis. The normalized enrichment scores (NES) and false discovery rate (FDR) are indicated. (B) Plots showing the cell cycle scores of transcriptionally defined LT-HSCs, ST-HSCs, and MPPs that were isolated from scRNAseq data sets of WT and STAT5-deficient BM LK cells (STAT5 WT, n&#x000a0;=&#x000a0;3; STAT5KO, n&#x000a0;=&#x000a0;3). (C) Line graphs showing the proportion of ESLAM HSCs that past first, second, third, and fourth divisions at given timepoints (y-axis) in the single cell in&#x000a0;vitro analysis (mean&#x000a0;&#x000b1; SEM). The results are from 3 biological replicates across 3 experiments. (D) Bar plots (left) showing the mean fluorescent intensity (MFI) of pSTAT5 antibody staining of ESLAM HSCs by intracellular flow-cytometry analysis in unstimulated maintenance culture conditions<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref> (SCF/IL-11) or TPO (200&#x000a0;ng/mL) positive control conditions (mean&#x000a0;&#x000b1; SEM). Right; representative histogram of the intracellular flow-cytometry analysis showing the intensity of pSTAT5 staining in each condition. The results are from 3 biological replicates. (E) Bar plot showing the number of cells in each well at day 5 from an initial culture of 50 ESLAM HSCs in SCF/IL11 maintenance conditions. The number of cells that expressed mature lineage markers (Ter119<sup>+</sup>, Ly6g<sup>+</sup>, CD11b<sup>+</sup>, NK1.1<sup>+</sup>, B220<sup>+</sup>, CD19<sup>+</sup>, or CD3e<sup>+</sup>) and the number of lineage-negative cells are shaded in different colours (mean&#x000a0;&#x000b1; SEM). The results are from 9 to 7 biological replicates across 4 experiments. (F) Bar plot showing the proportion of cells that expressed mature lineage markers after 5&#x000a0;days in culture that originated from 50 ESLAM HSCs (mean&#x000a0;&#x000b1; SEM). (G) Bar plot showing the proportion of cells that expressed specific mature lineage markers for monocytes (Mons) and granulocytes (Grans; Ly6g<sup>+</sup>), Grans and macrophages (MacsCD11b<sup>+</sup>), erythroid (Ery; Ter119<sup>+</sup>), lymphocytes (LYMs; CD3e<sup>+</sup>/CD19<sup>+</sup>/B220<sup>+</sup>), and natural killer cells (NK; NK1.1<sup>+</sup>) after 5&#x000a0;days in culture that originated from 50 ESLAM HSCs (mean&#x000a0;&#x000b1; SEM). (H) Bar plot showing the frequency of Ter119<sup>+</sup> cells after 5&#x000a0;days in culture that originated from 50 ESLAM HSCs (mean&#x000a0;&#x000b1; SEM). Asterisks indicate significant differences as determined by Student <italic>t</italic> test (&#x02217;&#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .0001; &#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .001; &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .01; &#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.05). KO, knockout.</p></caption><graphic xlink:href="BLOODA_ADV-2024-014046-gr2ae"/><graphic xlink:href="BLOODA_ADV-2024-014046-gr2fh"/></fig></p><p id="p0095">Ki-67/DAPI staining showed that, when compared with WT mice, STAT5-deficient mice had increased proportions of ESLAM HSCs in G<sub>0</sub> and reduced proportions in G<sub>1</sub>, although this did not reach statistical significance (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;2</xref>G-I). However, it is challenging to detect increases in dormancy in populations that are already highly quiescent, and the Ki-67/DAPI analysis represents a snapshot, which may not capture subtle but relevant changes in quiescence maintenance. We therefore measured the division kinetics of single HSCs (as previously described<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref>). STAT5-deficient ESLAM HSCs were indeed slower to enter their first and subsequent divisions (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C), indicating transient cell cycle arrest or compounded delays in cell cycle entry, thus demonstrating that STAT5 is required for normal HSC cell cycle progression.</p><p id="p0100">The functional consequences of a STAT5 deficiency described above reflect the combined effect of losing both pSTAT5 and uSTAT5. To identify the consequences attributable to a loss of uSTAT5, experimental conditions that precluded STAT5 phosphorylation were required. We suspected that stem-cell factor (SCF) and IL-11 media (previously described to maintain HSCs<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref>) would not activate STAT5 phosphorylation in HSCs. Indeed, the pSTAT5 levels in ESLAM HSCs cultured in SCF/IL-11 were not significantly higher than those in cytokine-starved conditions (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>D). After 5&#x000a0;days in this culture condition, STAT5-deficient ESLAM HSCs produced fewer cells overall with markedly fewer lineage-negative cells (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>E) and an increase in the proportion of lineage-positive cells (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>F). The proportion of each lineage increased (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>G; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;2</xref>J-M) with the erythroid lineage (Ter119<sup>+</sup>) reaching statistical significance (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>H). Similar results were obtained with ESLAM HSCs cultured for 4 or 6&#x000a0;days (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;2</xref>N) with no difference in the frequency of apoptotic cells (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;2</xref>O). These data indicate that loss of uSTAT5 is responsible for increased HSC differentiation and reduced generation of lineage-negative cells.</p><p id="p0105">Together, these results therefore demonstrate that STAT5 loss leads to an unusual HSC phenotype with reduced cell cycle progression but yet increased differentiation.</p></sec><sec id="sec3.3"><title>Unphosphorylated STAT5 constrains HSC differentiation and upregulates transcriptional programs associated with HSC maintenance</title><p id="p0110">To further explore the role of uSTAT5 in HSCs, we used a lentiviral expression approach. STAT5B is the dominant form of STAT5 protein in multipotent HPC7 cells<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> and long-term repopulating HSCs.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> STAT5-YF, which prevents phosphorylation at the critical tyrosine residue, was introduced into STAT5<sup>+/+</sup> or STAT5<sup>&#x02212;/&#x02212;</sup> ESLAM HSCs, along with EV controls (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A). STAT5-YF and EV constructs showed comparable expansion and survival in STAT5<sup>+/+</sup> and STAT5<sup>&#x02212;/&#x02212;</sup> HSC-derived clones (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>A-B), but STAT5-YF expression led to reduced differentiation in the STAT5<sup>+/+</sup> and STAT5<sup>&#x02212;/&#x02212;</sup> clones (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>B). These observations are in accord with our studies of STAT5<sup>&#x02212;/&#x02212;</sup> HSCs, which indicated that loss of uSTAT5 enhances their differentiation (see above). Thus, both the knockout and overexpression approaches indicate that uSTAT5 constrains HSC differentiation. STAT5-YF expression increased the total STAT5 levels two- to threefold in Lin<sup>&#x02212;</sup>Sca1<sup>&#x02212;</sup>cKit<sup>+</sup> (LSKs; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>C-D), and so our results indicate that the functional consequence of STAT5-YF is a two- to threefold increase in uSTAT5, because the vast majority of potentially phosphorylatable STAT5 (ie, can be phosphorylated by thrombopoietin) remains unphosphorylated in SCF/IL-11<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref> media (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>E).<fig id="fig3"><label>Figure&#x000a0;3.</label><caption><p><bold>Unphosphorylated STAT5 constrains HSC differentiation and upregulates transcriptional programs associated with HSC maintenance.</bold> (A) Schematic diagram showing the experimental outline of the ex&#x000a0;vivo functional analysis of STAT5-deficient or WT ESLAM (CD45<sup>+</sup>CD150<sup>+</sup>CD48<sup>&#x02212;</sup>EPCR<sup>+</sup>) HSCs that were transduced with lentivirus containing STAT5B-YF or EV in maintenance cultures.<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref> After 3&#x000a0;days of transduction, GFP<sup>+</sup> living cells were FACS sorted into single-cell assays. (B) Bar plots showing the proportion of cells expressing mature lineage markers (Ter119<sup>+</sup>/Ly6g<sup>+</sup>/CD11b<sup>+</sup>/B220<sup>+</sup>/CD3e<sup>+</sup>). Each dot represents a single clone and bars represent the mean lineage-positive marker frequency (&#x000b1;SEM). Asterisks indicate significant differences as determined by Student <italic>t</italic> tests (&#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .001; &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .01). The results are from 6 to 5 independent biological replicates across 5 experiments in STAT5<sup>+/+</sup> settings and 4 to 3 independent biological replicates across 3 experiments in STAT5<sup>&#x02212;/&#x02212;</sup> settings. (C) Schematic diagram showing the outline of the scRNAseq analysis of WT ESLAM HSCs that were transduced with lentivirus containing STAT5B-YF or EV in maintenance cultures<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref> and that were allowed to expand for 5&#x000a0;days. GFP<sup>+</sup> living cells were then sorted for 10X Genomics scRNAseq. (D) Bar plots showing the proportion of annotated cell types in GFP<sup>+</sup> HSC-derived cultures after 5&#x000a0;days in SCF/IL-11 cultures; single cells were projected onto a previously published scRNAseq data set of LK HSPC cells<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> and then onto a phenotypically-defined HSPC data set,<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> and cell types were annotated based on their nearest neighbors to ascribe cell identity and cell type annotation. The results are from 2 independent biological replicates in 2 experiments. (E) Gene set enrichment plot showing that STAT5-YF&#x02013;infected, transcriptionally defined LT-HSCs (n&#x000a0;=&#x000a0;83) are depleted in a DNA replication gene signature when compared with EV-infected LT-HSCs (n&#x000a0;=&#x000a0;53). The NES (&#x02212;5.24) and FDR (&#x0003c;0.001) are indicated. (F) Left: bar plots showing the cell cycle phase frequency of ESLAM HSC-derived cultures infected with either EV (n&#x000a0;=&#x000a0;5) or STAT5-YF (n&#x000a0;=&#x000a0;4) lentivirus after 5&#x000a0;days in maintenance culture media.<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref> The cell cycle status was derived from Ki67/DAPI staining (right). G<sub>0</sub> represents quiescent cells that are Ki67<sup>low</sup>DAPI<sup>low</sup>; G<sub>1</sub> represents cells in the early growth phase, which are Ki67<sup>high</sup>DAPI<sup>low</sup>; S-G2-M represents cells in DNA synthesis, late growth, and mitosis stages of active cell cycling and are Ki67<sup>high</sup>DAPI<sup>high</sup>. (G) Violin plot showing the geometric mean distribution of HSC scores in LT-HSCs expressing STAT5B-YF or EV. The HSC score was calculated using the HSC score tool that identifies potential mouse BM HSCs from scRNAseq data.<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> This tool considers the expression of genes that are either positively or negatively corelated with HSC long-term repopulating capacity.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> (H) Violin plots showing significantly differentially expressed genes that are positively associated with functional long-term repopulating HSCs (<italic>Pdzk1ip1</italic>, <italic>Mettl7a1</italic>, <italic>Mllt3</italic>, and <italic>Gimap1</italic>), negatively associated with functional long-term repopulating HSCs (<italic>Serpinb1a</italic> and <italic>Hsp90aa1</italic>), or genes with reported functions in maintaining HSCs (<italic>Hlf</italic>, <italic>Chd9</italic>, <italic>Pbx1</italic>, and <italic>Plxnc1</italic>). All data were combined from 2 independent experiments. Asterisks indicate significant differences as determined by Student <italic>t</italic> tests (&#x02217;&#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .0001; &#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .001; &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .01; &#x02217;<italic>P</italic>&#x000a0;&#x0003c; .05). GMP, granulocyte-macrophage progenitor; LMPP, lymphoid-myeloid progenitor; MEP, Meg/Ery progenitors; ns, not significant.</p></caption><graphic xlink:href="BLOODA_ADV-2024-014046-gr3"/></fig></p><p id="p0115">The transcriptional consequences of STAT5-YF expression in ESLAM HSCs were explored using 10x Genomics scRNAseq (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C). Because STAT5<sup>&#x02212;/&#x02212;</sup> and STAT5<sup>+/+</sup> HSCs responded similarly to STAT5-YF overexpression and because STAT5-deficient HSCs are less abundant, STAT5<sup>+/+</sup> HSCs were used for this analysis. <italic>Stat5b</italic> transcripts increased twofold in STAT5-YF&#x02013;infected cells (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>F), consistent with the protein levels (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>B). Infected cells were projected onto a previously published scRNAseq data set of LK cells<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> and then a phenotypically-defined HSPC data set,<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> and cell types were annotated based on their nearest neighbors. When compared with control EV cultures, STAT5-YF cultures contained fewer differentiated cell types (eg, granulocyte-macrophage progenitors, Meg/Ery progenitors, and neutrophils) but more early stem/progenitor cells (LT-HSCs and ST-HSCs; <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>G). These results align well with our functional evidence that STAT5-YF constrains differentiation.</p><p id="p0120">Within transcriptionally defined LT-HSCs, STAT5-YF expression was associated with the upregulation of 321 genes and downregulation of 120 genes (<xref rid="appsec1" ref-type="sec">supplemental Table&#x000a0;3</xref>), representing both&#x000a0;direct and indirect consequences of STAT5-YF expression. The expression levels of pSTAT5 target genes (<italic>Pim1, Ccnd1, Mcl1</italic>, and <italic>Sod2</italic>) were unaffected by STAT5-YF expression (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>H), and gene set enrichment analysis failed to identify enrichments or depletions in canonical STAT5 target gene sets (data not shown), indicating that STAT5-YF is not exerting a dominant negative effect. Consistent with this concept, the vast majority of phosphorylatable STAT5 remains unphosphorylated in HSCs cultured in SCF/IL11 (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>D; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>E), however, our results cannot completely exclude the existence of very low levels of pSTAT5 below our detection levels.</p><p id="p0125">In HPC7 cells, we have previously shown that uSTAT5 repressed several megakaryocytic genes (<italic>Mpl, Vwf, Gp9,</italic> and <italic>F2r</italic>) and that it competed with ERG in regulating <italic>Mpl</italic> and <italic>F2r</italic>. We therefore explored whether similar effects could be found in highly purified HSCs. The expression levels of <italic>Mpl, Vwf, Gp9</italic>, and <italic>F2r</italic> were not increased in STAT5<sup>&#x02212;/&#x02212;</sup> HSCs or reduced in STAT5-YF&#x02013;expressing HSCs (<xref rid="appsec1" ref-type="sec">supplementary Figure&#x000a0;3</xref>I), which likely reflect different transcriptional programs within HPC-7 cells (similar to Meg/Ery progenitors and derived from embryonic stem cells) and HSCs.</p><p id="p0130">Cell cycle gene signatures were significantly depleted in STAT5-YF&#x02013;infected LT-HSCs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>E; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>J). More STAT5-YF LT-HSCs were in the G<sub>0</sub>/G<sub>1</sub> phases (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>K), and Ki67/DAPI analysis in STAT5<sup>+/+</sup> ESLAM-derived cultures confirmed that STAT5-YF expression increased the frequency of HSCs in G<sub>0</sub> (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>F), collectively indicating that STAT5-YF expression is associated with increased HSC quiescence. STAT5-YF&#x02013;expressing LT-HSCs exhibited higher HSC scores than EV expressing HSCs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>G) when a previously described algorithm was used, which identifies durable, long-term repopulating HSCs<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> and takes into account the expression of genes that correlate either positively or negatively with HSC function.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> STAT5-YF HSCs also exhibited higher HSC scores using 2 other published HSC signatures (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>L).<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref> Indeed, positively-associated HSC score genes were upregulated in STAT5-YF LT-HSCs, whereas anticorrelated genes were downregulated, and other genes reported to promote HSC maintenance were also upregulated (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>H).</p><p id="p0135">Together, our data therefore demonstrate that STAT5-YF restrains HSC differentiation, increases HSC quiescence, and regulates transcriptional networks associated with increased HSC maintenance.</p></sec><sec id="sec3.4"><title>Unphosphorylated STAT5 enhances HSPC clonogenicity in&#x000a0;vitro and HSC maintenance in&#x000a0;vivo</title><p id="p0140">We subsequently explored the effect of STAT5-YF expression on HSC function (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A). In serial colony replating assays, STAT5<sup>+/+</sup> HSCs expressing STAT5-YF displayed enhanced colony generation in 4 independent experiments (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>B; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;4</xref>A), demonstrating that uSTAT5 is sufficient to enhance the generation of clonogenic progeny by WT HSCs. The introduction of STAT5-YF had no effect on the replating of STAT5<sup>&#x02212;/&#x02212;</sup> HSCs, but these cells produced far fewer colonies for a shorter duration than WT cells (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;4</xref>B), indicating a requirement for pSTAT5 in the replating assay, likely through its role in driving proliferation.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> Indeed, STAT5 phosphorylation was readily detectable in HSCs cultured in the replating assay media, which contained IL-3 and IL-6 (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;4</xref>C).<fig id="fig4"><label>Figure&#x000a0;4.</label><caption><p><bold>Unphosphorylated STAT5B enhances HSPC clonogenicity in&#x000a0;vitro and HSC maintenance in&#x000a0;vivo.</bold> (A) Schematic diagram showing the experimental outline of the serial colony replating assays of STAT5-deficient or WT ESLAM (CD45<sup>+</sup>CD150<sup>+</sup>CD48<sup>&#x02212;</sup>EPCR<sup>+</sup>) HSCs that were transduced with lentivirus containing STAT5B-YF or EV in SCF/IL-11 maintenance cultures. After 3&#x000a0;days of transduction, GFP<sup>+</sup> living cells were sorted for serial colony replating assays. (B) Bar plots showing the transformed colony numbers derived from WT HSPCs transduced with YF or EV lentivirus. Transformed colony counts&#x000a0;= ((colony number&#x000a0;&#x000d7; dilution factor) <inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">&#x000f7;</mml:mo></mml:mrow></mml:math></inline-formula> starting number of HSCs) (mean&#x000a0;&#x000b1; SEM). The results were from 4 independent experiments and 7 biological replicates. Asterisks indicate the significant differences as determined by Mann-Whitney <italic>U</italic> tests (&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .01). (C) Bar plots showing the transformed colony numbers of STAT5-deficient HSPCs transduced with YF or EV lentivirus. Transformed colony counts&#x000a0;= ((colony number&#x000a0;&#x000d7; dilution factor) <inline-formula><mml:math id="M2" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">&#x000f7;</mml:mo></mml:mrow></mml:math></inline-formula> starting number of HSCs) (mean&#x000a0;&#x000b1; SEM). The results were from 3 independent experiments and 4 biological replicates. Asterisks indicate significant differences as determined by Mann-Whitney <italic>U</italic> tests (&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .05). (D) Schematic diagram showing the outline of the in&#x000a0;vivo functional analysis of WT ESLAM HSCs that were transduced with lentivirus containing STAT5B-YF or EV. FACS-sorted WT ESLAM HSCs (CD45.2<sup>+</sup>) were infected with lentivirus and cultured for 3&#x000a0;days in maintenance cultures and then an equal number of GFP<sup>+</sup> cells were FACS sorted (112 GFP<sup>+</sup> cells per recipient) and injected into irradiated recipients (CD45.1<sup>+</sup>) with 3&#x000a0;&#x000d7; 10<sup>5</sup> competitor BMMNCs (CD45.1<sup>+</sup>/CD45.2<sup>+</sup>). Donor chimerism was monitored every 28&#x000a0;days for more than 6&#x000a0;months. Secondary transplantation was then performed using 5&#x000a0;&#x000d7; 10<sup>6</sup> BMMNCs from primary recipients. BMMNCs from 1 primary recipient were transplanted into up to 2 recipients. (E) Connected line graph showing donor chimerism in primary recipients (mean&#x000a0;&#x000b1; SEM) (experiment described in panel D). Chimerism was derived as the ratio of donor: (donor&#x000a0;+ competitor). (F) Connected line graph showing donor chimerism in secondary recipients (mean&#x000a0;&#x000b1; SEM) (experiment described in panel D). Chimerism was derived as the ratio of donor/(donor&#x000a0;+ competitor). (G) Bar plots showing donor chimerism in total BMMNCs and ESLAM HSCs in the BM of the primary transplant recipients (mean&#x000a0;&#x000b1; SEM). (H) Bar plots showing donor chimerism in total BMMNCs and ESLAM HSCs in the BM of the secondary transplant recipients (mean&#x000a0;&#x000b1; SEM). (I) Bar plots showing the ratio of ESLAM HSC donor chimerism to total BMMNC chimerism in primary recipient BM (mean&#x000a0;&#x000b1; SEM; dotted line indicating 1:1 ratio). (J) Bar plots showing the ratio of ESLAM HSC donor chimerism to total BMMNC chimerism in secondary recipient BM (mean&#x000a0;&#x000b1; SEM; dotted line indicating 1:1 ratio). Chimerism was derived as the ratio of donor/(donor&#x000a0;+ competitor). Asterisks indicate significant differences as determined by Student <italic>t</italic> tests (&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .01; &#x02217;<italic>P</italic>&#x000a0;&#x0003c; .05).</p></caption><graphic xlink:href="BLOODA_ADV-2024-014046-gr4"/></fig></p><p id="p0145">In competitive transplantation experiments (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>D), when compared with control EV-infected HSCs, those that carried STAT5-YF generated peripheral blood donor chimerism that was modestly reduced in primary recipients (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>E) and dramatically reduced in secondary recipients (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>F; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;4</xref>D). Furthermore, when compared with control EV-infected HSCs, HSCs infected with STAT5-YF gave rise to a reduction in the total BM chimerism but increased ESLAM-HSC chimerism in primary recipients (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>G), an observation that was even more striking in secondary recipients (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>H). Within individual primary recipients, the ratio of HSC chimerism to total BM chimerism was substantially higher for mice that received STAT5-YF HSCs than for those that had received EV HSCs (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>I). This pattern was even more striking in secondary transplant recipients (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>J).</p><p id="p0150">Together, our results therefore indicate that STAT5-YF expression enhances the clonogenicity of HSCs ex&#x000a0;vivo and increases HSC chimerism while restricting their repopulating capacity in&#x000a0;vivo.</p></sec><sec id="sec3.5"><title>Ruxolitinib enhances HSPC clonogenicity and maintains transplantable HSCs</title><p id="p0155">JAK inhibitors, such as ruxolitinib, are predicted to increase the ratio of uSTAT5 to pSTAT5. Indeed, ruxolitinib treatment of cells with activated JAK/STAT signaling (driven by mutant JAK2 or mutant CALR), led to a dramatic reduction in pSTAT5 without a fall in total STAT5 protein levels (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>A). In ESLAM HSCs, the levels of pSTAT5 (but not pSTAT1 or pSTAT3) were induced fourfold in a ruxolitinib-sensitive manner when exposed to SCF, IL3, and IL6 (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A-B; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>B-C). The total STAT5 protein levels were unchanged (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C), and pSTAT5 target genes such as <italic>Cish</italic> and <italic>Pim1</italic> were downregulated in HSCs exposed to ruxolitinib (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>D).<fig id="fig5"><label>Figure&#x000a0;5.</label><caption><p><bold>Ruxolitinib (RUX) enhances HSPC clonogenicity and maintains transplantable HSCs.</bold> (A) Schematic diagram showing intracellular flow cytometric analysis of STAT5 proteins in RUX-treated WT ESLAM HSCs (CD45<sup>+</sup>CD150<sup>+</sup>CD48<sup>&#x02212;</sup>EPCR<sup>+</sup>). WT ESLAM HSCs were sorted into serum&#x02013;starved media and starved for 1 hour before a 30-minute stimulation with complete medium containing IL-3, IL-6, and SCF in the presence or absence of RUX,<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> and a stimulation cocktail containing thrombopoietin (THPO), Flt3-L, and interferon alfa for positive control was included. Cells were then fixed and stained for intracellular flow cytometry. (B) Bar plots showing the MFI of pSTAT5 antibody staining in ESLAM HSCs, described in panel A, normalized to the unstimulated condition, which is indicated with the dotted line (mean&#x000a0;&#x000b1; SEM). Each dot represents the MFI of ESLAMs from a single mouse. The results are from 3 independent experiments. (C) Bar plots showing the MFI of total-STAT5 (tSTAT5) antibody staining in ESLAM HSCs, described in panel A, normalized to STAT5-deficient HSPCs, which is indicated with the dotted line (mean&#x000a0;&#x000b1; SEM). The results are from 3 independent experiments. (D) Bar plots showing cell number per well in HSC-derived cultures at each dose of RUX or vehicle after 7&#x000a0;days (mean&#x000a0;&#x000b1; SEM). A total of 50 ESLAMs were seeded per well in 96-well plates in IL-3/IL-6/SCF<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> cultures and were treated with DMSO or the indicated doses of RUX. The results are from 6 independent experiments. (E) Bar plot showing the proportion of cells that expressed lineage-positive markers (Ter119<sup>+</sup>/Ly6g<sup>+</sup>/CD11b<sup>+</sup>/B220<sup>+</sup>/CD3e<sup>+</sup>) after 7&#x000a0;days in culture at different concentrations (nM) of RUX (mean&#x000a0;&#x000b1; SEM). A total of 50 ESLAMs were seeded per well in 96-well plates in IL-3/IL-6/SCF<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> cultures and were treated with the indicated doses of RX. The results are from 6 independent experiments. (F) Bar plots showing the clone survival rate of single HSCs after 5&#x000a0;days in culture. Single ESLAM HSCs were sorted per well and treated with vehicle or RUX. Clone survival rate was the proportion of wells that contained cells at day 5. Each dot represents the frequency of surviving clones from each of 3 independent experiments; the bars show the mean&#x000a0;&#x000b1; SEM. (G) Schematic diagram showing the serial colony replating assays and in&#x000a0;vivo functional analysis for ESLAM HSCs treated with RUX or vehicle. A total of 50 WT ESLAM HSCs were sorted per well into complete media<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> with scaled doses of RUX or vehicle. Cells were harvested after 7&#x000a0;days and plated into serial colony replating assays. ESLAM HSC (CD45.2<sup>+</sup>)&#x02013;derived cells after 5&#x000a0;days in culture were harvested and transplanted into lethally irradiated recipient mice (CD45.1<sup>+</sup>) with 3&#x000a0;&#x000d7; 10<sup>5</sup> fresh BMMNCs from competitor mice (CD45.1<sup>+</sup>/CD45.2<sup>+</sup>). Blood was analyzed every 28&#x000a0;days for 6&#x000a0;months. Secondary transplants were then set up by transplanting 3&#x000a0;&#x000d7; 10<sup>6</sup> BM cells from the primary transplant recipients. (H) Bar plots showing the number of colonies produced by HSC-derived cultures treated with vehicle or RUX (250 or 1000 nM) for 7&#x000a0;days, normalized to the number of colonies produced by vehicle-treated cultures at each week of replating. The results are shown as mean&#x000a0;&#x000b1; SEM and were from 5 independent experiments, 3 of which included 1000 nM. Asterisks indicate significant differences as determined by Mann-Whitney <italic>U</italic> tests (&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .01; &#x02217;<italic>P</italic>&#x000a0;&#x0003c; .05). (I) Scatter dot plot with linear regression line of best fit showing the peripheral blood donor chimerism in primary (left) and secondary (right) recipients transplanted with 5-day ex&#x000a0;vivo cultured HSCs with RUX or vehicle. A total of 50 ESLAMs from WT mice were seeded per well in IL-3/IL-6/SCF culture conditions and given DMSO or 250 nM of RUX for 5&#x000a0;days before the cells were harvested and pooled for each condition, and an equivalent of 10 starting ESLAMs was transplanted per recipient with 3&#x000a0;&#x000d7; 10<sup>5</sup> competitor BM cells. Each dot indicates the mean donor chimerism and are shown as mean&#x000a0;&#x000b1; SEM. Black asterisks indicate significant differences in the slopes of the linear regression modeling that compared chimerism of RUX-treated donor cell with DMSO-treated donor cell chimerism in the primary recipients (&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .01). Blue asterisks indicate significant differences in the y-intercepts of linear regressions modeling that compared chimerisms of RUX-treated donor cells with DMSO-treated donor cells in secondary transplants (&#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .001). (J) Bar plots showing the donor chimerism within the ESLAM HSC compartment at the end of primary and secondary recipients of 5-day ex&#x000a0;vivo cultured HSCs with RUX or vehicle. The data are shown as the mean&#x000a0;&#x000b1; SEM. (K) Violin plot showing the geometric mean distribution of HSC scores in LT-HSCs from the 10x scRNAseq data set of the cells treated with RUX or DMSO. The scores were calculated using the HSC score tool that identifies potential mouse BM HSCs from scRNAseq data.<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> This tool considers the expression of genes that are either positively or negatively correlated with HSC long-term repopulating capacity.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> (L) Violin plots showing significantly differentially expressed genes that are positively associated with functional long-term repopulating HSCs (<italic>Pdzk1ip1</italic>, <italic>Mettl7a1</italic>, <italic>Mllt3</italic>, and <italic>Gimap6</italic>), negatively associated with functional long-term repopulating HSCs (<italic>Hsp90aa1</italic> and <italic>Cdk6</italic>), or genes with reported functions in maintaining HSCs (<italic>Hlf</italic>, <italic>Pbx1</italic>, <italic>Chd9</italic>, and <italic>Plxnc1</italic>). All data were combined from 2 independent experiments. Asterisks indicate significant differences as determined by Student <italic>t</italic> tests (&#x02217;&#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .0001; &#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .001; &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .01; &#x02217;<italic>P</italic>&#x000a0;&#x0003c; .05) unless otherwise indicated. ns, not significant.</p></caption><graphic xlink:href="BLOODA_ADV-2024-014046-gr5ah"/><graphic xlink:href="BLOODA_ADV-2024-014046-gr5il"/></fig></p><p id="p0160">Ruxolitinib reduced, in a dose-dependent manner, the progeny generated by ESLAM HSCs (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>D; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>E-F) and the proportion of lineage-positive cells (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>E; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>G-H). Two other JAK inhibitors, fedratinib and momelotinib, similarly reduced the expansion and differentiation of ESLAM HSCs in culture (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>I-J). Treatment with ruxolitinib was not accompanied by a reduction in HSPC viability; even single ESLAM HSCs cultured with high doses of ruxolitinib (eg, 1000 nM, well above the therapeutic range) showed no difference in the proportion of wells containing 1 or more viable cells at 5&#x000a0;days (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>F). Moreover, treatment of lineage-depleted BM cells with ruxolitinib overnight led to apoptosis of mature cell types, but it had little effect on LK cells, suggesting that ruxolitinib does not affect survival of early HSPCs (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>K).</p><p id="p0165">To investigate the effect of ruxolitinib on HSC function, serial colony replating assays and competitive transplants were performed (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>G). When compared with vehicle-treated HSCs, those exposed to ruxolitinib formed significantly more colonies in the final week of replating assays (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>H; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>L-M), indicating that ruxolitinib increased the maintenance of clonogenic HSPCs in precultures. In 2 independent competitive repopulation experiments, vehicle-treated control cells gave rise to a donor peripheral blood chimerism that gradually fell over the 5-month study period (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>I; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>N) as previously reported for cultured HSC donors.<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> In marked contrast, ruxolitinib-treated HSCs gave rise to a donor peripheral blood chimerism at levels that were initially lower than that of controls and then were maintained or increased. In secondary recipients, donor HSCs originally treated with ruxolitinib displayed significantly higher peripheral blood chimerism levels (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>I; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>O). Moreover, primary recipient mice that received HSCs precultured with ruxolitinib displayed increased ESLAM HSC chimerism levels, an effect that was even more marked in secondary recipients (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>J).</p><p id="p0170">scRNAseq was used to explore the transcriptional consequences of ruxolitinib (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>P). Ruxolitinib-treated ESLAM HSC-derived cultures exhibited a reduction in the expression of canonical pSTAT5 target genes (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>Q) and contained more transcriptionally defined LT-HSCs and ST-HSCs (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>R). When compared with control LT-HSCs, ruxolitinib-treated LT-HSCs were depleted in cell cycle gene signatures (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>S) and possessed a greater frequency of cells in G<sub>0</sub>/G<sub>1</sub> (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>T). These data were confirmed by Ki67/DAPI analysis at 18 hours and 5&#x000a0;days of treatment (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>U-V), collectively showing that ruxolitinib promotes HSC quiescence ex&#x000a0;vivo.</p><p id="p0175">Consistent with their increased quiescence, ruxolitinib-treated LT-HSCs showed increased HSC fitness scores (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>K; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>W) when using the 3 different published scoring methods<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref><sup>,</sup><xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref> that also demonstrated increased HSC&#x000a0;scores for STAT5-YF&#x02013;treated LT-HSCs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>G; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;3</xref>J). Ruxolitinib-treated LT-HSCs also showed increased scores for a signature derived by comparing STAT5-YF&#x02013;expressing LT-HSCs with EV-transduced controls (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>X). Furthermore, ruxolitinib increased the expression of positively-associated HSC score genes, reduced the expression of negatively-associated HSC score genes, and increased the expression of multiple other genes associated with HSC maintenance (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>L) in a manner similar to STAT5-YF expression (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>H). Several of these genes (eg, <italic>Pdzk1ip1, Gimap6, Hlf, Plxnc1</italic>, and <italic>Chd9</italic>) had previously been identified by chromatin-immunoprecipitation studies<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> as direct targets of uSTAT5 (<xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;5</xref>Y).</p><p id="p0180">Together, our data demonstrate that ruxolitinib pretreatment reduced HSC differentiation, increased HSC quiescence, and enhanced the maintenance of transplantable HSCs during ex&#x000a0;vivo culture. Moreover, the transcriptional consequences of ruxolitinib closely paralleled those observed for STAT5-YF&#x02013;expressing HSCs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>G-H), indicating that the effects of ruxolitinib are mediated, at least in part, by uSTAT5.</p></sec><sec id="sec3.6"><title>Ruxolitinib maintains murine and human MPN HSPCs</title><p id="p0185">Ruxolitinib alleviates symptoms, reduces splenomegaly, and modestly extends the overall survival in a subset of patients with MPN with advanced disease.<xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref> However, it has little or no effect on the allele burden and disease progression,<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref><sup>,</sup><xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> suggesting that ruxolitinib does not eradicate malignant HSCs. This has been attributed to ruxolitinib having a narrow therapeutic window as a consequence of its dose-limiting toxicity.<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref><sup>,</sup><xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> However, our data raise the possibility that JAK inhibitors might also inherently promote the maintenance of mutant HSCs by increasing the levels of uSTAT5.</p><p id="p0190">We therefore studied the effect of ruxolitinib on CALR-mutant HSCs derived from a knockin mouse model<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> that carried a CALR-52 bp deletion mutation commonly observed in human patients with MPN<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> and known to activate JAK/STAT signaling<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A). Ruxolitinib reduced the number of progeny cells generated by CALR-mutant ESLAM HSCs and also the proportion of lineage-positive cells (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B-C). Ruxolitinib pretreatment also enhanced the replating capacity of cells derived from CALR-mutant ESLAM HSCs (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>D-E; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;6</xref>A-B), demonstrating that ruxolitinib maintains clonogenic HSPCs.<fig id="fig6"><label>Figure&#x000a0;6.</label><caption><p><bold>RUX maintains murine and human MPN HSPCs.</bold> (A) Schematic diagram showing the in&#x000a0;vitro functional assays of murine ESLAM HSCs (CD45<sup>+</sup>CD150<sup>+</sup>CD48<sup>&#x02212;</sup>EPCR<sup>+</sup>) treated with RUX or DMSO. ESLAM HSCs were FACS isolated from CALRdel/del (n&#x000a0;=&#x000a0;4) mutant mice and were then cultured for 7&#x000a0;days in IL-3/IL-6/SCF media<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> with DMSO or 250 nM of RUX before analysis by flow cytometry. (B) Bar plots showing cell number per well in HSC-derived cultures treated with vehicle or 250 nM RUX after 7&#x000a0;days (mean&#x000a0;&#x000b1; SEM). (C) Bar plots showing the proportion of cells that expressed lineage-positive markers (Ter119<sup>+</sup>/Ly6g<sup>+</sup>/CD11b<sup>+</sup>/B220<sup>+</sup>/CD3e<sup>+</sup>) after 7&#x000a0;days in culture with DMSO or 250 nM RUX (mean&#x000a0;&#x000b1; SEM). Asterisks indicate significant differences as determined by Student <italic>t</italic> tests (&#x02217;&#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .001; &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .01; &#x02217;<italic>P</italic>&#x000a0;&#x0003c; .05). (D) Schematic diagram showing the serial replating assays that investigated the effect of RUX on ESLAM HSCs isolated from WT and CALRdel/del mutant mice. Sorted ESLAM HSCs were cultured for 7&#x000a0;days in IL-3/IL-6/SCF media<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> with DMSO or 250 nM RUX and then subjected to serial colony replating assays. (E) Bar plots showing the fold change in the number of colonies produced by HSC-derived cultures treated with vehicle or 250 nM RUX for 7&#x000a0;days, normalized to the number of colonies produced by vehicle-treated cultures at each week of replating. The results are from 2 independent experiments and are shown as mean&#x000a0;&#x000b1; SEM. Asterisks indicate significant differences as determined by Mann-Whitney <italic>U</italic> tests (&#x02217;<italic>P</italic>&#x000a0;&#x0003c; .05) (F) Schematic diagram showing that HSCs (MPP1&#x02013;LT-HSCs; CD34<sup>+</sup>CD38<sup>&#x02212;</sup>CD45RA<sup>&#x02212;</sup>) cells were sorted from healthy human platelet apheresis donor cone samples or from the peripheral blood of patients with myelofibrosis into 96-well plates (400 cells per well) and cultured in high-cytokine, serum-free medium (EXPER cytokine media)<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> with scaled doses of RUX or vehicle control (DMSO). After 7&#x000a0;days, the HSC-derived cultures were plated in serial colony replating assays in methylcellulose. Healthy donors were all male and between 48 and 69 years of age. Among the donor patients with myelofibrosis, 3 patients carried a JAK2 V617F mutation and were all male between the ages of 65 to 70 years and 1 donor carried a CALR 52&#x000a0;bp deletion mutation and was a 70 year old female at the time of sample collection. (G) Bar plots showing the fold change in the number of colonies produced by HSPCs that were isolated from healthy donors and cultured for 7&#x000a0;days in the presence of RUX, normalized to the number of colonies that were produced by HSPCs after culturing for 7&#x000a0;days with DMSO. The data are shown as log<sub>2</sub>(fold change) from DMSO. Left showing fold change in colony numbers in the first round of colony formation (2&#x000a0;weeks in methylcellulose). Right showing fold change in colony numbers in the second round of colony formation (4&#x000a0;weeks in methylcellulose). From the data of the 4 healthy donors, each dot represents the mean fold change between technical replicates of a single donor. (H) Table&#x000a0;showing the significance values (<italic>P</italic> value) from the estimated marginal (EM) means statistics derived from comparisons between DMSO and RUX conditions using a generalized mixed linear model applied to the raw colony counts used to generate <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>G. (I) Bar plots showing the fold change in number of colonies produced by HSPCs that were isolated from patients with myelofibrosis and cultured for 7&#x000a0;days in the presence of RUX, normalized to the number of colonies produced by HSPCs cultured for 7&#x000a0;days with DMSO. The data are shown as log<sub>2</sub>(fold change) from DMSO. Left showing the fold change in colony numbers in the first round of colony formation (2&#x000a0;weeks in methylcellulose). Right showing the fold change in colony numbers in the second round of colony formation (4&#x000a0;weeks in methylcellulose). Each dot represents the average fold change from each of 4 patients with myelofibrosis, and the bars represent the mean&#x000a0;&#x000b1; SEM. (J) Table&#x000a0;showing the significance values (<italic>P</italic> value) from EM means statistics derived from comparisons between DMSO and RUX conditions using a generalized mixed linear model statistic applied to colony counts used to generate <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>I.</p></caption><graphic xlink:href="BLOODA_ADV-2024-014046-gr6"/></fig></p><p id="p0195">To investigate whether ruxolitinib maintained human HSCs in ex&#x000a0;vivo cultures, CD34<sup>+</sup>CD38<sup>&#x02212;</sup>CD45RA<sup>&#x02212;</sup> HSPCs were purified from apheresis cones derived from 4 platelet donors, grown in cytokine-rich, serum-free culture conditions<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> with or without ruxolitinib, and their progeny cells were assessed in serial colony replating assays (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>F). These human cell cultures did not contain albumin, which binds ruxolitinib, necessitating the use of lower ruxolitinib doses as previously described.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> After 2&#x000a0;weeks, ruxolitinib did not increase colony formation and even reduced colony output at the highest dose (500 nM), but by 4&#x000a0;weeks, it increased colony formation in all individuals at all doses tested with 10 nM and 50 nM (similar to concentrations obtained in patients in&#x000a0;vivo<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> after accounting for albumin) showing the greatest benefit (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>G-H; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;6</xref>C-E; <xref rid="appsec1" ref-type="sec">supplemental Table&#x000a0;5</xref>).</p><p id="p0200">Ruxolitinib had a similar effect on HSPCs (CD34<sup>+</sup>CD38<sup>&#x02212;</sup>CD45RA<sup>&#x02212;</sup>) derived from the peripheral blood of 4 patients with myelofibrosis with high white blood cell counts, none of whom had previously received ruxolitinib or interferon. Three patients were positive for the JAK2V617F mutation, and 1 patient had a CALR deletion mutation. After 2&#x000a0;weeks, ruxolitinib had little effect on the&#x000a0;colony output except at the highest dose, but at 4&#x000a0;weeks, it substantially increased the colony output in all 4 patients with 10 nM and 50 nM concentrations showing the greatest benefit (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>I-J; <xref rid="appsec1" ref-type="sec">supplemental Figure&#x000a0;6</xref>F-H; <xref rid="appsec1" ref-type="sec">supplemental Table&#x000a0;6</xref>).</p><p id="p0205">Together, these data demonstrate that ruxolitinib maintained cultured murine myeloproliferative HSCs, human normal HSPCs, and human myeloproliferative HSPCs.</p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0210">Our results demonstrate that STAT5 loss is accompanied not only by reduced HSC numbers but also by a substantial impairment in HSC that was associated with reduced cell cycle entry and increased differentiation. Prompted by this unusual phenotype, we&#x000a0;showed that uSTAT5 promotes maintenance and constrains differentiation and proliferation of HSCs. Ruxolitinib, a JAK1/2 inhibitor widely used clinically, increases uSTAT5 levels and enhances the maintenance of WT and myeloproliferative HSCs from both mice and humans.</p><p id="p0215">An intimate relationship between proliferation and differentiation has long been recognized in studies of HSC biology. Many genetic (eg, ablation of CDKi<xref rid="bib75" ref-type="bibr">75</xref>, <xref rid="bib76" ref-type="bibr">76</xref>, <xref rid="bib77" ref-type="bibr">77</xref> or MEK1<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref>) or environmental manipulations (eg, infections or inflammation) that induce HSC proliferation and functional exhaustion are associated with increased differentiation.<xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref>, <xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref> In contrast, many of those that produce increased HSC quiescence are accompanied by reduced differentiation (eg, Neo1 downregulation<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> or Atad3a deletion<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref>). However, we showed here that highly purified STAT5-deficient HSCs display transcriptional evidence of reduced cell cycling, together with functional evidence of reduced cell cycle entry, and yet are more prone to differentiation. Bunting and colleagues have previously reported that STAT5-deficient LSK or CD34<sup>&#x02212;</sup>LSK HSCs displayed increased cell cycling.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> However, the frequencies of quiescent cells in their WT control populations were lower than those observed in the ESLAM HSCs here (84% vs 91%), suggesting that cell populations gated for cell cycle analysis in the previous reports contained a higher frequency of more proliferative progenitors (presumably ST-HSC/MPP). The decreased frequency of primitive HSCs in STAT5<sup>&#x02212;/&#x02212;</sup> mice likely led to a higher fraction of more proliferative ST-HSC/MPPs, thus increasing the proliferation scores for populations containing such cells.</p><p id="p0220">Our demonstration that STAT5 not only induces HSC proliferation but also represses HSC differentiation was reminiscent of previous results, which showed that uSTAT5 and pSTAT5 have separate transcriptional roles in megakaryocytic differentiation of multipotent HPC7 cells.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> We therefore explored the possibility that the functional consequences of STAT5 loss in HSCs might represent a compound phenotype that involves loss of both the uSTAT5 and pSTAT5 transcriptional programs. Two aspects of our studies are of particular note.</p><p id="p0225">First, our results indicate that uSTAT5 constrains HSC differentiation (as shown by both knockout and lentiviral expression approaches) and HSC proliferation and also enhances HSC maintenance as assessed by serial replating and transplantation of STAT5-YF&#x02013;expressing cells. In the latter studies, STAT5-YF increased donor chimerism within the HSC compartment in both primary and secondary recipients but reduced donor chimerism within whole BM, indicating that STAT5-YF&#x02013;expressing HSCs are retained in the HSC compartment and are less likely to differentiate. Second, these functional changes reflected altered HSC transcriptional programs including signatures of reduced differentiation, increased quiescence, and increased stemness as assessed by several different scoring systems.</p><p id="p0230">Our results highlight the need to take the signaling environment into account when interpreting the consequences of manipulating a STAT. Thus, using culture conditions that preclude significant STAT5 phosphorylation, the consequences of up- or downregulating STAT5 can be attributed to an effect on uSTAT5. However, we cannot completely exclude potential confounding effects of low levels of endogenous pSTAT5 when assessing the effect of STAT5-YF expression in WT HSCs. Our results also underline the challenges inherent to disentangling the different biologic effects of uSTAT5 and pSTAT5. For example, a requirement for pSTAT5 in replating assays precluded analysis of the ability of STAT5-YF to rescue STAT5-null HSCs. Tools that specifically deplete uSTAT5 are currently lacking but would greatly aid in the dissection of the distinct physiological roles of uSTAT5 and pSTAT5.</p><p id="p0235">It is interesting to consider our results in the light of data that HSCs can be expanded using culture conditions that include high TPO concentrations (100&#x000a0;ng/mL).<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref> This observation is in contrast with other reports that showed that low TPO<xref rid="bib86" ref-type="bibr"><sup>86</sup></xref> and low cytokine environments<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref> better maintain HSC function and that injection of TPO or a TPO mimetic reduces HSC numbers and HSC function in&#x000a0;vivo.<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref> Together, these data indicate that the effect of TPO is complex and may be concentration and/or context dependent. TPO-driven HSC expansion may require other features of the Wilkinson expansion cultures (eg, presence of polyvinal alcohol, absence of albumin, hypoxic incubation<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref>).</p><p id="p0240">Our results also have therapeutic implications. First, they raise the possibility that ruxolitinib could be a useful strategy to enhance ex&#x000a0;vivo maintenance of HSCs for gene therapies. Consistent with this concept, human HSPCs cultured in gene therapy conditions display a rapid upregulation of JAK/STAT signaling, and its inhibition improved their long-term repopulation.<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref> Second, in patients with an MPN,<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref><sup>,</sup><xref rid="bib90" ref-type="bibr"><sup>90</sup></xref> JAK inhibitors have little if any effect on the level of the mutant clone.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> A protective effect of ruxolitinib on mutant HSPCs may contribute to the limited efficacy of JAK inhibitors. Moreover, an accumulation of mutant HSCs poised to differentiate may also contribute to the JAK-inhibitor discontinuation syndrome, characterized by a rapid life-threatening MPN resurgence after JAK-inhibitor withdrawal.<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref> The cytokine environments of endogenous HSCs in their various niches remain poorly understood and so further studies will be needed to explore the HSC effects of ruxolitinib in&#x000a0;vivo. However, our results raise the possibility that targeting uSTAT5 or total STAT5 activity may represent attractive therapeutic approaches for myeloid malignancies associated with JAK activation.</p></sec><sec sec-type="COI-statement" id="coi0010"><p id="p0245">Conflict-of-interest disclosure: A.R.G. and J.L. report serving as consultants for Incyte. E.L. reports receiving research funds from GlaxoSmithKline and Commonwealth Serum Laboratories <funding-source id="gs14"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008322</institution-id><institution>Behring</institution></institution-wrap></funding-source>. The remaining authors declare no competing financial interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Orkin</surname><given-names>SH</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name></person-group><article-title>Hematopoiesis: an evolving paradigm for stem cell biology</article-title><source>Cell</source><volume>132</volume><issue>4</issue><year>2008</year><fpage>631</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">18295580</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Laurenti</surname><given-names>E</given-names></name><name><surname>G&#x000f6;ttgens</surname><given-names>B</given-names></name></person-group><article-title>From haematopoietic stem cells to complex differentiation landscapes</article-title><source>Nature</source><volume>553</volume><issue>7689</issue><year>2018</year><fpage>418</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">29364285</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>KK</given-names></name><name><surname>Boles</surname><given-names>NC</given-names></name><etal/></person-group><article-title>Less is more: unveiling the functional core of hematopoietic stem cells through knockout mice</article-title><source>Cell Stem Cell</source><volume>11</volume><issue>3</issue><year>2012</year><fpage>302</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">22958929</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>EM</given-names></name></person-group><article-title>Inflammation: a key regulator of hematopoietic stem cell fate in health and disease</article-title><source>Blood</source><volume>130</volume><issue>15</issue><year>2017</year><fpage>1693</fpage><lpage>1698</lpage><pub-id pub-id-type="pmid">28874349</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Mitchell</surname><given-names>CA</given-names></name><name><surname>Passegu&#x000e9;</surname><given-names>E</given-names></name></person-group><article-title>Inflammatory signaling regulates hematopoietic stem and progenitor cell development and homeostasis</article-title><source>J&#x000a0;Exp Med</source><volume>218</volume><issue>7</issue><year>2021</year><object-id pub-id-type="publisher-id">e20201545</object-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>S</given-names></name><name><surname>Trumpp</surname><given-names>A</given-names></name><name><surname>Milsom</surname><given-names>MD</given-names></name></person-group><article-title>Causes and consequences of hematopoietic stem cell heterogeneity</article-title><source>Cell Stem Cell</source><volume>22</volume><issue>5</issue><year>2018</year><fpage>627</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">29727678</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>SC</given-names></name><name><surname>Bach</surname><given-names>EA</given-names></name></person-group><article-title>JAK/STAT signaling in stem cells and regeneration: from Drosophila to vertebrates</article-title><source>Development</source><volume>146</volume><issue>2</issue><year>2019</year><object-id pub-id-type="publisher-id">dev167643</object-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>E</given-names></name><name><surname>Staudt</surname><given-names>LM</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name></person-group><article-title>Janus kinase deregulation in leukemia and lymphoma</article-title><source>Immunity</source><volume>36</volume><issue>4</issue><year>2012</year><fpage>529</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">22520846</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Gotthardt</surname><given-names>D</given-names></name><name><surname>Trifinopoulos</surname><given-names>J</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name><name><surname>Putz</surname><given-names>EM</given-names></name></person-group><article-title>JAK/STAT cytokine signaling at the crossroad of NK cell development and maturation</article-title><source>Front Immunol</source><volume>1462</volume><issue>2</issue><year>2019</year><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>KL</given-names></name><name><surname>Brockwell</surname><given-names>NK</given-names></name><name><surname>Parker</surname><given-names>BS</given-names></name></person-group><article-title>JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression</article-title><source>Cancers</source><volume>11</volume><issue>12</issue><year>2019</year><object-id pub-id-type="publisher-id">2002</object-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>AJ</given-names></name><name><surname>Putoczki</surname><given-names>T</given-names></name></person-group><article-title>JAK-STAT signalling pathway in cancer</article-title><source>Cancers</source><volume>12</volume><issue>7</issue><year>2020</year><fpage>1971</fpage><pub-id pub-id-type="pmid">32698360</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Moriggl</surname><given-names>R</given-names></name><name><surname>Topham</surname><given-names>DJ</given-names></name><name><surname>Teglund</surname><given-names>S</given-names></name><etal/></person-group><article-title>Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells</article-title><source>Immunity</source><volume>10</volume><issue>2</issue><year>1999</year><fpage>249</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">10072077</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Kieslinger</surname><given-names>M</given-names></name><name><surname>Woldman</surname><given-names>I</given-names></name><name><surname>Moriggl</surname><given-names>R</given-names></name><etal/></person-group><article-title>Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation</article-title><source>Genes Dev</source><volume>14</volume><issue>2</issue><year>2000</year><fpage>232</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">10652277</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Di</surname><given-names>L</given-names></name><etal/></person-group><article-title>Stat5 is essential for early B cell development but not for B cell maturation and function</article-title><source>J&#x000a0;Immunol</source><volume>179</volume><issue>2</issue><year>2007</year><fpage>1068</fpage><lpage>1079</lpage><pub-id pub-id-type="pmid">17617599</pub-id>
</element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Socolovsky</surname><given-names>M</given-names></name><name><surname>Fallon</surname><given-names>AEJ</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Brugnara</surname><given-names>C</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><article-title>Fetal anemia and apoptosis of red cell progenitors in Stat5a&#x02212;/&#x02212;5b&#x02212;/&#x02212; mice: a direct role for Stat5 in Bcl-XL induction</article-title><source>Cell</source><volume>98</volume><issue>2</issue><year>1999</year><fpage>181</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">10428030</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Socolovsky</surname><given-names>M</given-names></name><name><surname>Nam</surname><given-names>H</given-names></name><name><surname>Fleming</surname><given-names>MD</given-names></name><name><surname>Haase</surname><given-names>VH</given-names></name><name><surname>Brugnara</surname><given-names>C</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><article-title>Ineffective erythropoiesis in Stat5a&#x02212;/&#x02212;5b&#x02212;/&#x02212; mice due to decreased survival of early erythroblasts</article-title><source>Blood</source><volume>98</volume><issue>12</issue><year>2001</year><fpage>3261</fpage><lpage>3273</lpage><pub-id pub-id-type="pmid">11719363</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Levy</surname><given-names>DE</given-names></name></person-group><article-title>Comparative evolutionary genomics of the STAT family of transcription factors</article-title><source>JAK-STAT</source><volume>1</volume><issue>1</issue><year>2012</year><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">24058748</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X-W</given-names></name><name><surname>Wynshaw-Boris</surname><given-names>A</given-names></name><etal/></person-group><article-title>An indirect effect of Stat5a in IL-2&#x02013;induced proliferation: a critical role for Stat5a in IL-2&#x02013;mediated IL-2 receptor &#x003b1; chain induction</article-title><source>Immunity</source><volume>7</volume><issue>5</issue><year>1997</year><fpage>691</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">9390692</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Imada</surname><given-names>K</given-names></name><name><surname>Bloom</surname><given-names>ET</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><etal/></person-group><article-title>Stat5b is essential for natural killer cell&#x02013;mediated proliferation and cytolytic activity</article-title><source>J&#x000a0;Exp Med</source><volume>188</volume><issue>11</issue><year>1998</year><fpage>2067</fpage><lpage>2074</lpage><pub-id pub-id-type="pmid">9841920</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Udy</surname><given-names>GB</given-names></name><name><surname>Towers</surname><given-names>RP</given-names></name><name><surname>Snell</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression</article-title><source>Proc Natl Acad Sci U S A</source><volume>94</volume><issue>14</issue><year>1997</year><fpage>7239</fpage><lpage>7244</lpage><pub-id pub-id-type="pmid">9207075</pub-id>
</element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Teglund</surname><given-names>S</given-names></name><name><surname>McKay</surname><given-names>C</given-names></name><name><surname>Schuetz</surname><given-names>E</given-names></name><etal/></person-group><article-title>Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses</article-title><source>Cell</source><volume>93</volume><issue>5</issue><year>1998</year><fpage>841</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">9630227</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Watford</surname><given-names>WT</given-names></name><etal/></person-group><article-title>Stat5a/b are essential for normal lymphoid development and differentiation</article-title><source>Proc Natl Acad Sci U S A</source><volume>103</volume><issue>4</issue><year>2006</year><fpage>1000</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">16418296</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Hoelbl</surname><given-names>A</given-names></name><name><surname>Kovacic</surname><given-names>B</given-names></name><name><surname>Kerenyi</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation</article-title><source>Blood</source><volume>107</volume><issue>12</issue><year>2006</year><fpage>4898</fpage><lpage>4906</lpage><pub-id pub-id-type="pmid">16493008</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Bunting</surname><given-names>KD</given-names></name><name><surname>Bradley</surname><given-names>HL</given-names></name><name><surname>Hawley</surname><given-names>TS</given-names></name><name><surname>Moriggl</surname><given-names>R</given-names></name><name><surname>Sorrentino</surname><given-names>BP</given-names></name><name><surname>Ihle</surname><given-names>JN</given-names></name></person-group><article-title>Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5</article-title><source>Blood</source><volume>99</volume><issue>2</issue><year>2002</year><fpage>479</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">11781228</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Riedlinger</surname><given-names>G</given-names></name><name><surname>Miyoshi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation</article-title><source>Mol Cell Biol</source><volume>24</volume><issue>18</issue><year>2004</year><fpage>8037</fpage><lpage>8047</lpage><pub-id pub-id-type="pmid">15340066</pub-id>
</element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Medrzycki</surname><given-names>M</given-names></name><name><surname>Bunting</surname><given-names>ST</given-names></name><name><surname>Bunting</surname><given-names>KD</given-names></name></person-group><article-title>Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis</article-title><source>Oncotarget</source><volume>6</volume><issue>30</issue><year>2015</year><fpage>28961</fpage><lpage>28972</lpage><pub-id pub-id-type="pmid">26338970</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Wierenga</surname><given-names>ATJ</given-names></name><name><surname>Vellenga</surname><given-names>E</given-names></name><name><surname>Schuringa</surname><given-names>JJ</given-names></name></person-group><article-title>Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels</article-title><source>Mol Cell Biol</source><volume>28</volume><issue>21</issue><year>2008</year><fpage>6668</fpage><lpage>6680</lpage><pub-id pub-id-type="pmid">18779318</pub-id>
</element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Schuringa</surname><given-names>JJ</given-names></name><name><surname>Chung</surname><given-names>KY</given-names></name><name><surname>Morrone</surname><given-names>G</given-names></name><name><surname>Moore</surname><given-names>MAS</given-names></name></person-group><article-title>Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation</article-title><source>J&#x000a0;Exp Med</source><volume>200</volume><issue>5</issue><year>2004</year><fpage>623</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">15353555</pub-id>
</element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>R</given-names></name><name><surname>Aoki</surname><given-names>Y</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>K</given-names></name></person-group><article-title>Initiation of polyoma virus origin-dependent DNA replication through STAT5 activation by human granulocyte-macrophage colony-stimulating factor</article-title><source>Blood</source><volume>97</volume><issue>5</issue><year>2001</year><fpage>1266</fpage><lpage>1273</lpage><pub-id pub-id-type="pmid">11222369</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Gouilleux</surname><given-names>F</given-names></name><name><surname>Wakao</surname><given-names>H</given-names></name><name><surname>Mundt</surname><given-names>M</given-names></name><name><surname>Groner</surname><given-names>B</given-names></name></person-group><article-title>Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription</article-title><source>EMBO J</source><volume>13</volume><issue>18</issue><year>1994</year><fpage>4361</fpage><lpage>4369</lpage><pub-id pub-id-type="pmid">7925280</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>AJ</given-names></name><name><surname>Dai</surname><given-names>W</given-names></name><name><surname>O&#x02019;Mara</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Mechanism of activation of protein kinase JAK2 by the growth hormone receptor</article-title><source>Science (1979)</source><volume>344</volume><issue>6185</issue><year>2014</year><object-id pub-id-type="publisher-id">1249783</object-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Mui</surname><given-names>AL</given-names></name><name><surname>Wakao</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Miyajima</surname><given-names>A</given-names></name></person-group><article-title>Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation</article-title><source>EMBO J</source><volume>15</volume><issue>10</issue><year>1996</year><fpage>2425</fpage><lpage>2433</lpage><pub-id pub-id-type="pmid">8665850</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Pallard</surname><given-names>C</given-names></name><name><surname>Gouilleux</surname><given-names>F</given-names></name><name><surname>Benit</surname><given-names>L</given-names></name><etal/></person-group><article-title>Thrombopoietin activates a STAT5-like factor in hematopoietic cells</article-title><source>EMBO J</source><volume>14</volume><issue>12</issue><year>1995</year><fpage>2847</fpage><lpage>2856</lpage><pub-id pub-id-type="pmid">7796811</pub-id>
</element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Reich</surname><given-names>NC</given-names></name></person-group><article-title>STATs get their move on</article-title><source>JAK-STAT</source><volume>2</volume><issue>4</issue><year>2013</year><fpage>e27080</fpage><comment>e27080</comment><pub-id pub-id-type="pmid">24470978</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Croker</surname><given-names>BA</given-names></name><name><surname>Kiu</surname><given-names>H</given-names></name><name><surname>Nicholson</surname><given-names>SE</given-names></name></person-group><article-title>SOCS regulation of the JAK/STAT signalling pathway</article-title><source>Semin Cell Dev Biol</source><volume>19</volume><issue>4</issue><year>2008</year><fpage>414</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">18708154</pub-id>
</element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>B</given-names></name><name><surname>Kollmann</surname><given-names>S</given-names></name><name><surname>Pickem</surname><given-names>J</given-names></name><name><surname>Hoelbl-Kovacic</surname><given-names>A</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name></person-group><article-title>STAT5A and STAT5B-twins with different personalities in hematopoiesis and leukemia</article-title><source>Cancers</source><volume>11</volume><issue>11</issue><year>2019</year><fpage>1726</fpage><pub-id pub-id-type="pmid">31690038</pub-id>
</element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Halim</surname><given-names>CE</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Ong</surname><given-names>MS</given-names></name><name><surname>Yap</surname><given-names>CT</given-names></name></person-group><article-title>Involvement of STAT5 in oncogenesis</article-title><source>Biomedicines</source><volume>8</volume><issue>9</issue><year>2020</year><fpage>316</fpage><pub-id pub-id-type="pmid">32872372</pub-id>
</element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Wingelhofer</surname><given-names>B</given-names></name><name><surname>Neubauer</surname><given-names>HA</given-names></name><name><surname>Valent</surname><given-names>P</given-names></name><etal/></person-group><article-title>Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer</article-title><source>Leukemia</source><volume>32</volume><issue>8</issue><year>2018</year><fpage>1713</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">29728695</pub-id>
</element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Vogiatzi</surname><given-names>P</given-names></name><name><surname>Puhr</surname><given-names>M</given-names></name><etal/></person-group><article-title>Stat5 promotes metastatic behavior of human prostate cancer cells in&#x000a0;vitro and in&#x000a0;vivo</article-title><source>Endocr Relat Cancer</source><volume>17</volume><issue>2</issue><year>2010</year><fpage>481</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">20233708</pub-id>
</element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Moser</surname><given-names>C</given-names></name><name><surname>Ruemmele</surname><given-names>P</given-names></name><name><surname>Gehmert</surname><given-names>S</given-names></name><etal/></person-group><article-title>STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases</article-title><source>Neoplasia</source><volume>14</volume><issue>10</issue><year>2012</year><fpage>915</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">23097626</pub-id>
</element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>James</surname><given-names>C</given-names></name><name><surname>Ugo</surname><given-names>V</given-names></name><name><surname>Le Cou&#x000e9;dic</surname><given-names>J-P</given-names></name><etal/></person-group><article-title>A&#x000a0;unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</article-title><source>Nature</source><volume>434</volume><issue>7037</issue><year>2005</year><fpage>1144</fpage><lpage>1148</lpage><pub-id pub-id-type="pmid">15793561</pub-id>
</element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Baxter</surname><given-names>EJ</given-names></name><name><surname>Scott</surname><given-names>LM</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</article-title><source>Lancet</source><volume>365</volume><issue>9464</issue><year>2005</year><fpage>1054</fpage><lpage>1061</lpage><pub-id pub-id-type="pmid">15781101</pub-id>
</element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Nangalia</surname><given-names>J</given-names></name><name><surname>Massie</surname><given-names>CE</given-names></name><name><surname>Baxter</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2</article-title><source>N&#x000a0;Engl J Med</source><volume>369</volume><issue>25</issue><year>2013</year><fpage>2391</fpage><lpage>2405</lpage><pub-id pub-id-type="pmid">24325359</pub-id>
</element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Wadleigh</surname><given-names>M</given-names></name><name><surname>Cools</surname><given-names>J</given-names></name><etal/></person-group><article-title>Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</article-title><source>Cancer Cell</source><volume>7</volume><issue>4</issue><year>2005</year><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">15837627</pub-id>
</element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Klampfl</surname><given-names>T</given-names></name><name><surname>Gisslinger</surname><given-names>H</given-names></name><name><surname>Harutyunyan</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Somatic mutations of calreticulin in myeloproliferative neoplasms</article-title><source>N&#x000a0;Engl J Med</source><volume>369</volume><issue>25</issue><year>2013</year><fpage>2379</fpage><lpage>2390</lpage><pub-id pub-id-type="pmid">24325356</pub-id>
</element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Kralovics</surname><given-names>R</given-names></name><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Buser</surname><given-names>AS</given-names></name><etal/></person-group><article-title>A&#x000a0;gain-of-function mutation of JAK2 in myeloproliferative disorders</article-title><source>N&#x000a0;Engl J Med</source><volume>352</volume><issue>17</issue><year>2005</year><fpage>1779</fpage><lpage>1790</lpage><pub-id pub-id-type="pmid">15858187</pub-id>
</element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Gotlib</surname><given-names>J</given-names></name><etal/></person-group><article-title>A&#x000a0;double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis</article-title><source>N&#x000a0;Engl J Med</source><volume>366</volume><issue>9</issue><year>2012</year><fpage>799</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">22375971</pub-id>
</element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Gotlib</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I</article-title><source>Haematologica</source><volume>98</volume><issue>12</issue><year>2013</year><fpage>1865</fpage><lpage>1871</lpage><pub-id pub-id-type="pmid">24038026</pub-id>
</element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Kiladjian</surname><given-names>J-J</given-names></name><etal/></person-group><article-title>Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis</article-title><source>Blood</source><volume>122</volume><issue>25</issue><year>2013</year><fpage>4047</fpage><lpage>4053</lpage><pub-id pub-id-type="pmid">24174625</pub-id>
</element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Sureau</surname><given-names>L</given-names></name><name><surname>Orvain</surname><given-names>C</given-names></name><name><surname>Ianotto</surname><given-names>J-C</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis</article-title><source>Blood Cancer J</source><volume>11</volume><issue>7</issue><year>2021</year><fpage>135</fpage><pub-id pub-id-type="pmid">34315858</pub-id>
</element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Tse</surname><given-names>W</given-names></name><name><surname>Bunting</surname><given-names>KD</given-names></name></person-group><article-title>Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement</article-title><source>Blood</source><volume>113</volume><issue>20</issue><year>2009</year><fpage>4856</fpage><lpage>4865</lpage><pub-id pub-id-type="pmid">19258595</pub-id>
</element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Kollmann</surname><given-names>S</given-names></name><name><surname>Grausenburger</surname><given-names>R</given-names></name><name><surname>Klampfl</surname><given-names>T</given-names></name><etal/></person-group><article-title>A&#x000a0;STAT5B&#x02013;CD9 axis determines self-renewal in hematopoietic and leukemic stem cells</article-title><source>Blood</source><volume>138</volume><issue>23</issue><year>2021</year><fpage>2347</fpage><lpage>2359</lpage><pub-id pub-id-type="pmid">34320169</pub-id>
</element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>HL</given-names></name><name><surname>Hawley</surname><given-names>TS</given-names></name><name><surname>Bunting</surname><given-names>KD</given-names></name></person-group><article-title>Cell intrinsic defects in cytokine responsiveness of STAT5-deficient hematopoietic stem cells</article-title><source>Blood</source><volume>100</volume><issue>12</issue><year>2002</year><fpage>3983</fpage><lpage>3989</lpage><pub-id pub-id-type="pmid">12393407</pub-id>
</element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output</article-title><source>Exp Hematol</source><volume>35</volume><issue>11</issue><year>2007</year><fpage>1684</fpage><lpage>1694</lpage><pub-id pub-id-type="pmid">17976521</pub-id>
</element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hannah</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cytokine-induced megakaryocytic differentiation is regulated by genome-wide loss of a uSTAT transcriptional program</article-title><source>EMBO J</source><volume>35</volume><issue>6</issue><year>2016</year><fpage>580</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">26702099</pub-id>
</element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Schepers</surname><given-names>H</given-names></name><name><surname>van Gosliga</surname><given-names>D</given-names></name><name><surname>Wierenga</surname><given-names>ATJ</given-names></name><name><surname>Eggen</surname><given-names>BJL</given-names></name><name><surname>Schuringa</surname><given-names>JJ</given-names></name><name><surname>Vellenga</surname><given-names>E</given-names></name></person-group><article-title>STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells</article-title><source>Blood</source><volume>110</volume><issue>8</issue><year>2007</year><fpage>2880</fpage><lpage>2888</lpage><pub-id pub-id-type="pmid">17630355</pub-id>
</element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Iwama</surname><given-names>A</given-names></name><name><surname>Tadokoro</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis</article-title><source>J&#x000a0;Exp Med</source><volume>202</volume><issue>1</issue><year>2005</year><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">15998795</pub-id>
</element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Prins</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage</article-title><source>Blood</source><volume>131</volume><issue>6</issue><year>2018</year><fpage>649</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">29282219</pub-id>
</element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>K&#x000fc;hn</surname><given-names>R</given-names></name><name><surname>Schwenk</surname><given-names>F</given-names></name><name><surname>Aguet</surname><given-names>M</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group><article-title>Inducible gene targeting in mice</article-title><source>Science (1979)</source><volume>269</volume><issue>5229</issue><year>1995</year><fpage>1427</fpage><lpage>1429</lpage></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Dahlin</surname><given-names>JS</given-names></name><name><surname>Hamey</surname><given-names>FK</given-names></name><name><surname>Pijuan-Sala</surname><given-names>B</given-names></name><etal/></person-group><article-title>A single cell hematopoietic landscape resolves eight lineage trajectories and defects in Kit mutant mice</article-title><source>Blood</source><volume>131</volume><issue>21</issue><year>2018</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">29118004</pub-id>
</element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Nestorowa</surname><given-names>S</given-names></name><name><surname>Hamey</surname><given-names>FK</given-names></name><name><surname>Pijuan Sala</surname><given-names>B</given-names></name><etal/></person-group><article-title>A&#x000a0;single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation</article-title><source>Blood</source><volume>128</volume><issue>8</issue><year>2016</year><fpage>e20</fpage><lpage>e31</lpage><pub-id pub-id-type="pmid">27365425</pub-id>
</element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>DG</given-names></name><name><surname>Dykstra</surname><given-names>BJ</given-names></name><name><surname>Cheyne</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>E</given-names></name><name><surname>Eaves</surname><given-names>CJ</given-names></name></person-group><article-title>Steel factor coordinately regulates the molecular signature and biologic function of hematopoietic stem cells</article-title><source>Blood</source><volume>112</volume><issue>3</issue><year>2008</year><fpage>560</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">18502833</pub-id>
</element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Hamey</surname><given-names>FK</given-names></name><name><surname>G&#x000f6;ttgens</surname><given-names>B</given-names></name></person-group><article-title>Machine learning predicts putative hematopoietic stem cells within large single-cell transcriptomics data sets</article-title><source>Exp Hematol</source><volume>78</volume><year>2019</year><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">31513832</pub-id>
</element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>NK</given-names></name><name><surname>Kent</surname><given-names>DG</given-names></name><name><surname>Buettner</surname><given-names>F</given-names></name><etal/></person-group><article-title>Combined single-cell functional and gene expression analysis resolves heterogeneity within stem cell populations</article-title><source>Cell Stem Cell</source><volume>16</volume><issue>6</issue><year>2015</year><fpage>712</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">26004780</pub-id>
</element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Cabezas-Wallscheid</surname><given-names>N</given-names></name><name><surname>Buettner</surname><given-names>F</given-names></name><name><surname>Sommerkamp</surname><given-names>P</given-names></name><etal/></person-group><article-title>Vitamin A-retinoic acid signaling regulates hematopoietic stem cell dormancy</article-title><source>Cell</source><volume>169</volume><issue>5</issue><year>2017</year><fpage>807</fpage><lpage>823.e19</lpage><pub-id pub-id-type="pmid">28479188</pub-id>
</element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>EM</given-names></name><name><surname>Lakshminarasimhan</surname><given-names>R</given-names></name><name><surname>Techner</surname><given-names>J-M</given-names></name><etal/></person-group><article-title>Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons</article-title><source>J&#x000a0;Exp Med</source><volume>211</volume><issue>2</issue><year>2014</year><fpage>245</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">24493802</pub-id>
</element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Daniel</surname><given-names>P</given-names></name><name><surname>Jung</surname><given-names>PH</given-names></name><name><surname>Sam</surname><given-names>W</given-names></name><etal/></person-group><article-title>The stem/progenitor landscape is reshaped in a mouse model of essential thrombocythemia and causes excess megakaryocyte production</article-title><source>Sci Adv</source><volume>6</volume><issue>48</issue><year>2022</year><object-id pub-id-type="publisher-id">eabd3139</object-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Dykstra</surname><given-names>B</given-names></name><name><surname>Kent</surname><given-names>D</given-names></name><name><surname>Bowie</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term propagation of distinct hematopoietic differentiation programs in&#x000a0;vivo</article-title><source>Cell Stem Cell</source><volume>1</volume><issue>2</issue><year>2007</year><fpage>218</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">18371352</pub-id>
</element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Vannucchi</surname><given-names>Alessandro M</given-names></name><name><surname>te Boekhorst</surname><given-names>Peter AW</given-names></name><name><surname>Harrison</surname><given-names>Claire N</given-names></name><etal/></person-group><article-title>EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis</article-title><source>Haematologica</source><volume>104</volume><issue>5</issue><year>2019</year><fpage>947</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">30442723</pub-id>
</element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</article-title><source>N&#x000a0;Engl J Med</source><volume>363</volume><issue>12</issue><year>2010</year><fpage>1117</fpage><lpage>1127</lpage><pub-id pub-id-type="pmid">20843246</pub-id>
</element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Pecquet</surname><given-names>C</given-names></name><name><surname>Chachoua</surname><given-names>I</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants</article-title><source>Blood</source><volume>133</volume><issue>25</issue><year>2019</year><fpage>2669</fpage><lpage>2681</lpage><pub-id pub-id-type="pmid">30902807</pub-id>
</element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Belluschi</surname><given-names>S</given-names></name><name><surname>Calderbank</surname><given-names>EF</given-names></name><name><surname>Ciaurro</surname><given-names>V</given-names></name><etal/></person-group><article-title>Myelo-lymphoid lineage restriction occurs in the human haematopoietic stem cell compartment before lymphoid-primed multipotent progenitors</article-title><source>Nat Commun</source><volume>9</volume><issue>1</issue><year>2018</year><fpage>4100</fpage><pub-id pub-id-type="pmid">30291229</pub-id>
</element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>De Marinis</surname><given-names>E</given-names></name><name><surname>Ceccherelli</surname><given-names>A</given-names></name><name><surname>Quattrocchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models</article-title><source>Sci Rep</source><volume>9</volume><issue>1</issue><year>2019</year><object-id pub-id-type="publisher-id">16379</object-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>JG</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>McGee</surname><given-names>RF</given-names></name><etal/></person-group><article-title>The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers</article-title><source>J&#x000a0;Clin Pharmacol</source><volume>51</volume><issue>12</issue><year>2011</year><fpage>1644</fpage><lpage>1654</lpage><pub-id pub-id-type="pmid">21257798</pub-id>
</element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>P</given-names></name><name><surname>Yoshihara</surname><given-names>H</given-names></name><name><surname>Hosokawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>p57<sup>Kip2</sup> and p27<sup>Kip1</sup> cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70</article-title><source>Cell Stem Cell</source><volume>9</volume><issue>3</issue><year>2011</year><fpage>247</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">21885020</pub-id>
</element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Takeishi</surname><given-names>S</given-names></name><name><surname>Kanie</surname><given-names>T</given-names></name><etal/></person-group><article-title>p57 is required for quiescence and maintenance of adult hematopoietic stem cells</article-title><source>Cell Stem Cell</source><volume>9</volume><issue>3</issue><year>2011</year><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">21885021</pub-id>
</element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Rodrigues</surname><given-names>N</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Hematopoietic stem cell quiescence maintained by p21cip1/waf1</article-title><source>Science (2000)</source><volume>287</volume><issue>5459</issue><year>2000</year><fpage>1804</fpage><lpage>1808</lpage></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Baumgartner</surname><given-names>C</given-names></name><name><surname>Toifl</surname><given-names>S</given-names></name><name><surname>Farlik</surname><given-names>M</given-names></name><etal/></person-group><article-title>An ERK-dependent feedback mechanism prevents hematopoietic stem cell exhaustion</article-title><source>Cell Stem Cell</source><volume>22</volume><issue>6</issue><year>2018</year><fpage>879</fpage><lpage>892.e6</lpage><pub-id pub-id-type="pmid">29804890</pub-id>
</element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Essers</surname><given-names>MAG</given-names></name><name><surname>Offner</surname><given-names>S</given-names></name><name><surname>Blanco-Bose</surname><given-names>WE</given-names></name><etal/></person-group><article-title>IFN&#x003b1; activates dormant haematopoietic stem cells in&#x000a0;vivo</article-title><source>Nature</source><volume>458</volume><issue>7240</issue><year>2009</year><fpage>904</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">19212321</pub-id>
</element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Baldridge</surname><given-names>MT</given-names></name><name><surname>King</surname><given-names>KY</given-names></name><name><surname>Boles</surname><given-names>NC</given-names></name><name><surname>Weksberg</surname><given-names>DC</given-names></name><name><surname>Goodell</surname><given-names>MA</given-names></name></person-group><article-title>Quiescent haematopoietic stem cells are activated by IFN-&#x003b3; in response to chronic infection</article-title><source>Nature</source><volume>465</volume><issue>7299</issue><year>2010</year><fpage>793</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">20535209</pub-id>
</element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>S</given-names></name><name><surname>Hansson</surname><given-names>J</given-names></name><name><surname>Klimmeck</surname><given-names>D</given-names></name><etal/></person-group><article-title>Inflammation-induced emergency megakaryopoiesis driven by hematopoietic stem cell-like megakaryocyte progenitors</article-title><source>Cell Stem Cell</source><volume>17</volume><issue>4</issue><year>2015</year><fpage>422</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">26299573</pub-id>
</element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Bogeska</surname><given-names>R</given-names></name><name><surname>Mikecin</surname><given-names>A-M</given-names></name><name><surname>Kaschutnig</surname><given-names>P</given-names></name><etal/></person-group><article-title>Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging</article-title><source>Cell Stem Cell</source><volume>29</volume><issue>8</issue><year>2022</year><fpage>1273</fpage><lpage>1284.e8</lpage><pub-id pub-id-type="pmid">35858618</pub-id>
</element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Renders</surname><given-names>S</given-names></name><name><surname>Svendsen</surname><given-names>AF</given-names></name><name><surname>Panten</surname><given-names>J</given-names></name><etal/></person-group><article-title>Niche derived netrin-1 regulates hematopoietic stem cell dormancy via its receptor neogenin-1</article-title><source>Nat Commun</source><volume>12</volume><issue>1</issue><year>2021</year><fpage>608</fpage><pub-id pub-id-type="pmid">33504783</pub-id>
</element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Atad3a suppresses Pink1-dependent mitophagy to maintain homeostasis of hematopoietic progenitor cells</article-title><source>Nat Immunol</source><volume>19</volume><issue>1</issue><year>2018</year><fpage>29</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">29242539</pub-id>
</element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>AC</given-names></name><name><surname>Ishida</surname><given-names>R</given-names></name><name><surname>Kikuchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term ex&#x000a0;vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation</article-title><source>Nature</source><volume>571</volume><issue>7763</issue><year>2019</year><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">31142833</pub-id>
</element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Morikawa</surname><given-names>T</given-names></name><name><surname>Okinaga</surname><given-names>A</given-names></name><etal/></person-group><article-title>Environmental optimization enables maintenance of quiescent hematopoietic stem cells ex&#x000a0;vivo</article-title><source>Cell Rep</source><volume>28</volume><issue>1</issue><year>2019</year><fpage>145</fpage><lpage>158.e9</lpage><pub-id pub-id-type="pmid">31269436</pub-id>
</element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Oedekoven</surname><given-names>CA</given-names></name><name><surname>Belmonte</surname><given-names>M</given-names></name><name><surname>Bode</surname><given-names>D</given-names></name><etal/></person-group><article-title>Hematopoietic stem cells retain functional potential and molecular identity in hibernation cultures</article-title><source>Stem Cell Rep</source><volume>16</volume><issue>6</issue><year>2021</year><fpage>1614</fpage><lpage>1628</lpage></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Nakamura-Ishizu</surname><given-names>A</given-names></name><name><surname>Matsumura</surname><given-names>T</given-names></name><name><surname>Stumpf</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Thrombopoietin metabolically primes hematopoietic stem cells to megakaryocyte-lineage differentiation</article-title><source>Cell Rep</source><volume>25</volume><issue>7</issue><year>2018</year><fpage>1772</fpage><lpage>1785.e6</lpage><pub-id pub-id-type="pmid">30428347</pub-id>
</element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>CS</given-names></name><name><surname>Williams</surname><given-names>MJ</given-names></name><name><surname>Sham</surname><given-names>K</given-names></name><etal/></person-group><article-title>Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of cell cycle</article-title><source>Blood</source><volume>144</volume><issue>7</issue><year>2024</year><fpage>729</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">38805639</pub-id>
</element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Palandri</surname><given-names>F</given-names></name><name><surname>Palumbo</surname><given-names>GA</given-names></name><name><surname>Elli</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis</article-title><source>Blood Cancer J</source><volume>11</volume><issue>1</issue><year>2021</year><fpage>4</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">33414394</pub-id>
</element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary Material</title><p id="p0270">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplemental Tables 1-6</title></caption><media xlink:href="BLOODA_ADV-2024-014046-mmc1.xlsx"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2"><caption><title>Supplemental Methods, Figures, Legends for Tables, and References</title></caption><media xlink:href="BLOODA_ADV-2024-014046-mmc2.pdf"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0250">The authors thank all the technicians in the Green, Laurenti, and G&#x000f6;ttgens laboratories for their valuable technical assistance; R. Schulte, and C. Cossetti at the Cambridge Institute for Medical Research Flow Cytometry Core Facility for assistance with cell sorting; S. Mendez-Ferrer, D. Prins, S. Loughran, J. Deuel, and T. Klampfl for valuable constructive discussions; Justyna Rak for facilitating the approval of the experimental mouse work; M. Paramor for help with 10x single-cell RNA sequencing analysis; B. Arnold, M. Feetenby, N. Lumley, H. Bloy, L. Smith, and all the members of the Anne Mclaren Building Animal Core Facility for excellent technical assistance, animal welfare, and husbandry.</p><p id="p0255">The work in the Green, G&#x000f6;ttgens, and Laurenti laboratories was supported by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004440</institution-id><institution>Wellcome</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs1">203151/Z/16/Z</award-id>) and by the William B. Harris <funding-source id="gs2">Foundation</funding-source> (<award-id award-type="grant" rid="gs2">RG91681</award-id>), <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008288</institution-id><institution>Alborada Trust</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs3">RG109433</award-id>), and <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs4">RG83389</award-id>) for the <funding-source id="gs5">Green</funding-source> and <funding-source id="gs6">G&#x000f6;ttgens laboratories</funding-source>. E.L. was supported by <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004440</institution-id><institution>Wellcome</institution></institution-wrap></funding-source>&#x02013;<funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000288</institution-id><institution>Royal Society</institution></institution-wrap></funding-source> Sir Henry Dale Fellowship (107630/Z/15/Z) and a <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008594</institution-id><institution>European Hematology Association</institution></institution-wrap></funding-source> Non-Clinical Research Fellowship Award (RG20). N.M. was supported by a Deutsche Forschungsgemeinschaft Research Fellowship (ME 5209/1-1). G.M. is supported by the <funding-source id="gs11">Cancer Research UK Cambridge Cancer Centre</funding-source> (<award-id award-type="grant" rid="gs11">CTRQQR-2021\100012</award-id>). X.W. was supported by the <funding-source id="gs12"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (grant <award-id award-type="grant" rid="gs12">82100465</award-id>).</p><p id="p0260">C.J. was supported by a Medical Research Council Industrial Collaborative Awards in Science and Engineering <funding-source id="gs10">PhD studentship</funding-source> (<award-id award-type="grant" rid="gs10">1942750</award-id>).</p><sec id="sec5"><title>Authorship</title><p id="p0265">Contribution: M.J.W. and J.L. designed and conducted the experiments and analyzed the data; X.W. and H.P.B. performed the bioinformatic analyses; Q.W., S.J., and M.W. helped with intracellular flow; H.J.P. helped with blood phenotypic analysis of the STAT5 mouse model; G.G.-K. helped with fluorescence-activated cell sorting; N.K.W. and S.J.K. helped with single-cell RNA sequencing; G.S.V. helped with mice studies; R.H. helped to analyze the chromatin immunoprecipitation sequencing data; E.L., P.C., C.J., E.C., G.M., J.B., and N.M. helped with data interpretation and supervised the experiments with human HSCs; T.L.H., D.C.P., R.A., and R.S. provided technical assistance; P.C. helped with the human data statistical analyses; M.J.W., J.L., B.G., and A.R.G. wrote the manuscript; and J.L., B.G., and A.R.G. supervised the study.</p></sec></ack><fn-group><fn id="d36e682"><label>&#x02217;</label><p id="ntpara0010">M.J.W. and X.W. contributed equally to this study.</p></fn><fn id="d36e686"><label>&#x02020;</label><p id="ntpara0015">J.L., B.G., and A.R.G. are joint senior authors.</p></fn><fn id="d36e690"><p id="ntpara0020">The sequencing data have been deposited the Gene Expression Omnibus database (accession numbers GSE223366, GSE223632, GSE223680, and GSE260462).</p></fn><fn id="d36e693"><p id="ntpara0025">The full-text version of this article contains a data supplement.</p></fn></fn-group></back></article>